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Abstract 
 
Human ceruloplasmin (hCp) is the molecular linker between the copper and iron metabolism 
and its importance in the homeostasis of human body has been implied in some neurological dis-
eases. This plasma cuproenzyme has ferroxidase activity, oxidizing Fe2+ to Fe3+ and incorporating 
it into apotransferrin. hCp also has aminoxidase activity regulating the levels of amine stress hor-
mones in the bloodstream and brain. Thus, it is thought to have an important role in neurodegener-
ative diseases such as Alzheimer’s or Parkinson’s. To know more about the role of cerulopalsmin 
on the oxidation of neurotransmitters and on brain homeostasis it is essential to know which protein 
residues are implied in the binding and stabilization of these neurotransmitters. The primary source 
of structural information for protein-ligand complexes is X-ray crystallography. This is the most suc-
cessful method to determine macromolecular 3D structures but has some limitations as obtaining 
good diffracting protein crystals. 
In this study several attempts were made to achieve better hCp diffracting crystals and crys-
tals of hcp in complex with dopamine, L-dopa, epinephrine or serotonin in order to further deter-
mine its tridimensional structure. 
To improve hCp stabilization and solubility, differential scanning fluorimetry and dynamic 
light scattering were used in a search for a better buffer for crystallization. For hCp crystallization 
the vapour-diffusion technique was used in combination with several other methods. Commercial 
crystallization screens, crystal seeding, additives, crosslinking were the several methods used to 
improve crystal diffraction. 
Co-crystallization of hCp with neurotransmitters was performed with no success. Soaking of 
hCp crystals with the neurotransmitters was performed in an attempt to get crystals of the hCp-
neurotransmitter complexes. All crystals were sent for analysis at European Synchrotron Radiation 
Facility (ESRF) and structural data will be further processed.   
 
 
 
Key words: ceruloplasmin, neurotransmitters, epinephrine, dopamine, L-dopa, serotonin, protein 
crystals, crystallization, X-ray crystallography 
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Resumo 
 
A ceruloplasmina humana (hCp) é a ligação molecular entre o metabolismo do cobre e do 
ferro sendo de extrema importância para a homeostase corporal. Esta cuproenzima plasmática 
tem actividade de ferroxidase, oxidando Fe2+ a Fe3+ e incorporando-o na apotransferina. A hCp 
regula os níveis de hormonas na corrente sanguínea e no cérebro. Esta actividade de aminoxidase 
é muito importante podendo estar implicada em doenças neurodegenerativas como Alzheimer e 
Parkinson. Para de saber mais sobre o papel da ceruloplasmina na oxidação de neurotrans-
missores e na homeostase cerebral é necessário conhecer a natureza desta interacção e quais os 
resíduos proteicos envolvidos na ligação e estabilização destes complexos. A cristalografia de 
raios-X é a principal fonte de informação sobre complexos de proteína-ligandos. Apesar deste ser 
o método mais bem sucedido na determinação de estruturas 3D, tem algumas limitações, como a 
obtenção de cristais de proteína com bom poder de difracção. 
Neste estudo, foram feitas várias tentativas de melhorar cristais de hCp, já previamente 
descritos, e de obter cristais de hCp combinados com dopamina, L-dopa, epinefrina e serotonina 
de forma a poder obter a sua estrutura tridimensional. 
A solução tamponante onde é armazenada a proteína é muito importante para a sua estabi-
lização e solubilidade. Para melhorar estes aspectos da hCp utilizaram-se técnicas de fluorometria 
de varrimento diferencial (DSF) e varrimento de luz dinâmica (DLS). Para a cristalização da hCp 
usou-se o método de difusão de vapor combinado com outros métodos. Usaram-se screens de 
cristalização comerciais, semearam-se cristais, usaram-se aditivos e fez-se crosslinking para ten-
tar melhorar os cristais. 
A co-cristalização da ceruloplasmina com neurotransmissores não obteve sucesso e assim 
usaram-se cristais de hCp e mergulharam-se em neurotransmissores para tentar obter os cristais 
dos complexos. Todos os cristais foram enviados para análise no European Synchrotron Radiation 
Facility (ESRF) e os dados estruturais serão depois processados.   
 
 
 
Palavras-Chave: ceruloplasmina, neurotransmissores, epinefrina, dopamina, L-dopa, serotonina, 
cristais de proteína, cristalização, cristalografia de raios-X 
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1. INTRODUCTION 
Iron (Fe) and copper (Cu) are essential nutrients and its excess or deficit cause cell function 
fail leading to cell death. There is a metabolic linkage between these nutrients. Copper deficiency 
generates cellular iron deficiency, which in humans results in diminished work capacity, reduced 
intellectual capacity, diminished growth, alterations in bone mineralization, and diminished immune 
response which can be associated to several diseases and syndromes (Fox, 2003). In humans, the 
molecular linker between Fe and Cu was identified as being the plasma multi-copper oxidase 
ceruloplasmin (hCp). 
 
1.1. Copper and Iron Metabolism 
Copper and iron belong to the sub-family of transition elements that also includes zinc, nickel, 
cobalt, manganese and chromium. Cu has two oxidation states, cuprous (Cu1+) and cupric (Cu2+). 
Cu2+ is soluble, whereas Cu1+ solubility is in the sub-micromolar range. In biological systems, Cu is 
found mainly in the Cu2+ form, since in the presence of oxygen or other electron acceptors Cu1+ is 
readily oxidized to Cu2+. Cu oxidation is reversible as Cu2+ can accept an electron from strong 
reductants such as ascorbate and reduced glutathione (Galhardi et al., 2004).  
Iron exists in two stable oxidative states, ferrous (Fe2+) and ferric (Fe3+). In aqueous media, as 
plasma, Fe2+ is spontaneously oxidized by molecular oxygen to Fe3+ to form Fe(OH)3. The maximal 
solubility of Fe in an oxidative environment such as extracellular fluids is limited by the product solu-
bility constant of Fe(OH)3. At pH 7.0 the maximal solubility of Fe3+ is much lower than the maximal 
solubility of Fe2+. Thus, because of the low solubility of Fe in the presence of oxygen, over time or-
ganisms have been forced to evolve proteins that are able to bind Fe3+ and keep it thermodynami-
cally stable and, at the same time, kinetically available for biological processes. In vertebrates, Fe3+ 
binds to the plasma protein transferrin (Tf), which has two Fe3+ binding sites, and is delivered where 
needed (Aisen and Listowsky, 1980).  
The essentiality of iron and copper resides in their capacity to participate in one-electron ex-
change reactions, but the same property that makes them essential also generates free radicals that 
can be deleterious to cells. Thus, a concerted regulation of cellular copper and iron levels is crucial 
(Arredondo and Nunez, 2005). Fe2+ e Cu1+ transform through Fenton reaction, hydrogen peroxide 
(H2O2), a weak oxidant, into hydroxyl radical (OH.-), one of the most strong reactive species found in 
nature (Messerschmidt, 1989). This process was first described in 1894 by H.J.H. Fenton. In cellular 
reductive environment, Fe3+ or Cu2+ are reduced to Fe2+ or Cu1+ (Haber-Weiss reaction) generating 
a vicious cycle of OH.- production (figure 1.1). 
 
 
 
 
 
Figure 1.1 | Haber-Weiss cicle. Fenton and Hiber-Weiss reactions. 
 
Fenton reaction:  Fe2+ + H2O2  Fe3+ + OH- + .OH 
 
Haber-Weiss reaction:  Fe3+ + O2.-    Fe2+ + O2 
Fe3+ + H2O   Fe2+ + H+ + .OH 
Fe3+ + H2O2  Fe2+ + OOH. + H+ 
Chapter 1: Introduction 
“Human ceruloplasmin and neurotransmitters: complex stabilization and crystallization” 
   2 
Copper is a cofactor for numerous enzymes and plays an important role in central nervous 
system development; low concentrations of copper may result in incomplete development, whereas 
excess copper maybe injurious. Copper is required for the function of over 30 proteins, some critical 
for the metabolism, including superoxide dismutase (SOD), ceruloplasmin (hCp) or cytochrome c 
oxidase (COX). SOD converts superoxide anions to hydrogen peroxide for further dismutation by 
catalase. Ceruloplasmin oxidizes Fe2+, prior to Tf binding, and its absence does not produce marked 
changes in copper metabolism but leads to a gradual accumulation of Fe in liver and other tissues 
(Harris et al., 1995; Miyajima, 2003). Cu metabolism is altered in inflammation, infection, and cancer.  
Iron is required as a cofactor for several essential biochemical activities, such as oxygen 
transport, energy metabolism and DNA synthesis. The biological functions of iron are based on its 
flexible coordination and its favorable redox potential which allows its association with proteins, oxy-
gen binding, electron transfer and catalysis (Aisen et al., 2001). Iron is present in numerous essen-
tial proteins, such as the heme-containing proteins, electron transport chain and microsomal electron 
transport proteins, iron–sulfur proteins and enzymes such as ribonucleotide reductase, and tyrosine 
hydroxylase. Animal studies have revealed the Fe has relevant roles in neuronal and immune func-
tions (Beard et al., 2003). A poor diet on iron leads to irreversible alterations of brain function related 
to insufficient myelination and defective establishment of the dopaminergic tracts (Agarwal, 2001; 
Beard et al., 2003). The immune response is also affected and macrophages exhibit reduced bacte-
ricidal activity (Hallquist et al., 1992). 
 
1.1.1. Copper metabolism and homeostasis 
Cooper metabolism it still not fully understood in humans. An efficient Cu absorption varies 
depending upon the diet. Infancy represents one of the most critical periods in life in terms of Cu 
requirements because rapid growth increases Cu demands, whereas diets based on milk provide 
low amounts of the element (Lonnerdal, 1996). 40-50% Cu is absorbed by the small intestine, and 
transported to liver bound to specialized proteins, to be then distributed as a cofactor in 
cuproproteins. Excess Cu is disposed through bile and secreted into intestine in faeces (figure 1.2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 | Model of copper metabolism in humans. Ingested copper is absorbed from the gut, trans-
ported to liver bound to plasma proteins and distributed to cuproproteins. Copper is secreted into bile and 
excreted to the gut again in feces (personal communication by J.L. Collan to the IPCS, 1996). 
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Cu regulation seems to be very thigh. Body Cu levels are the result of a balance between Cu 
absorption and Cu excretion by the bile but although important advances have been made in the 
understanding of Cu excretion, the mechanisms that govern intestinal Cu absorption remain largely 
a mystery. In humans, Cu is absorbed primarily by the small intestine however the mechanism by 
which Cu enters the cells of the intestinal mucosa and crosses into the interstitial fluid and blood is 
not well understood. Once in blood stream, Cu binds to two proteins, albumin (Ab) and transcuprein 
(Tc). In hepatocytes Cu binds ceruloplasmin during its synthesis in the trans Golgi network.  
Cell Cu homeostasis, is maintained by two homologous cation transporting P-type ATPases, 
Menkes (MNK) and Wilson ATPases (WND) (Bull et al., 1993; Mercer et al., 1993; Tanzi et al., 
1993). They have similar structures and parallel roles in regulating the Cu status of cells and tissues 
and in supplying Cu to secreted cuproproteins. In most cells, MNK is responsible for excreting Cu 
when levels become high. In hepatocytes, this role is carried out by WND, disposing excess Cu 
through the bile. Both proteins supply Cu to the enzymes that are secreted by the cell by pumping 
the metal ion into the trans Golgi network, where the metal is incorporated into the apo-
ceruloplasmine. The regulation of Cu efflux by the cell is achieved by copper-induced relocalization 
from the trans Golgi network to the plasma membrane in the case of MNK or to an intracellular ve-
sicular compartment in the case of WND (figure 1.3).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 | Model of copper metabolism in hepatocytes. Copper crosses the plasma membrane through 
either Ctr1 (Cu transporter 1) or DMT1 (Divalent Metal Transporter 1), and is shuttled to the trans Golgi net-
work by chaperone Hah1/Atox1, which delivers Cu to the WND (or MNK in enterocytes). At Cu basal levels 
WND is located at the trans Golgi network but at higher levels is distributed into vesicles in cytoplasm. As Cu 
is stored its intracellular concentration decays and the ATPase returns to the trans Golgi network and the 
copper in vesicles is secreted into bile. In the Golgi complex Cu is incorporated into apo-hCp which is then 
released into plasma. The chaperone protein, Ccs (Copper chaperone for SOD1) delivers Cu to cytosolic 
SOD, which dismutates superoxide into hydrogen peroxide. Cox17 (cytochrome c oxidase copper chaper-
one) delivers Cu to the mitochondria, where it is required for cytochrome c oxidase. Glutathione (GSH) may 
also be a chaperone by binding Cu1+ and delivering it to metallothionein (MT) and to some copper-
dependent apoenzymes, such as SOD (Carroll et al., 2004). Adapted from (Arredondo and Nunez, 2005; 
Schaefer et al., 1999). 
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Ctr1 (Cu transporter 1), or hCtr1 in humans, promotes intestinal cells copper absorption and is 
also thought to facilitate the diffusion of Cu across the brush border membrane, even at low Cu con-
centrations (Moller et al., 2000). Another likely Cu transporter in the brush border is DMT1 (Divalent 
Metal Transporter 1), already described as a transporter of Fe2+, Cd2+ e Mn2+ (Arredondo et al., 
2003). Several other Cu chaperone were identified. These specialized proteins carry Cu to specific 
intracellular sites and enzymes, preventing the presence of free Cu ions in cell. The Cu chaperone 
HAH1/ATOX1 (Antioxidant protein 1 homolog) carries Cu ions to the trans Golgi network where de-
liver it to the P-type ATPase present there (WND in hepatocytes or MNK in enterocytes) (Hamza et 
al., 1999; Hung et al., 1998). Another chaperone is Ccs (Copper chaperone for SOD1) which deliv-
ers Cu to the SOD in cytoplasm. Cox17 (cytochrome c oxidase copper chaperone) takes Cu to the 
mitochondria, where it is required for cytochrome c oxidase. Glutathione (GTS) could also play the 
role of Cu chaperone delivering it to cytosolic metallothioneins (MT) or to hCtr1 in the plasma mem-
brane, but this pathway is not fully understood and remains to be further explored.  
Body copper homeostasis is the result of a balance between Cu absorption and Cu excretion 
by the bile (Linder and Hazegh-Azam, 1996). In the enterocytes, Cu is absorbed by Cu transporters 
and kept in the cytosol, binding to MTs. Cu accumulation in the hepatic or neuronal tissue results in 
copper intoxication and cell damage. When there is copper deficiency the iron uptake and transport 
within the body is affected, and iron tends to accumulate in several tissues. Thus, copper deficiency 
results in an anemia similar to that observed in iron deficiency.  
P-type ATPases, MNK and WND are very important in Cu homeostasis and its impaired re-
sults in a severe phenotype. Wilson’s disease, associated with WND ATPase impair, leads to copper 
accumulation in hepatic cells. Cu is not excreted into the bile nor is incorporated into hCp, causing 
chronic cirrhosis during childhood. Menkes’ disease, associated with fail of MNK ATPase, is caused 
by deficient Cu absorption in the intestine leading to severe fail of several organs and tissues (mus-
cle, kidney, lungs), bone anomalies and neuronal disorders.  
Cu metabolism is also altered in inflammation, infection, and cancer, and Cu and hCp levels 
rise, in contrast to Fe levels, which decline in serum during infection and inflammation. Synthesis 
and secretion of hCp by hepatocytes is stimulated by interleukin-1 and -6 (Linder and Hazegh-Azam, 
1996). Copper is essential for an efficient immune response, being necessary to the production of 
interleukin-2 by activated lymphocytic cells (Percival, 1998). In cancer, plasma hCp is positively cor-
related with disease stage and malignant tumors have concentrations of Cu that are often higher 
than those of their tissue of origin (Eagon et al., 1999). 
 
1.1.2. Iron metabolism and homeostasis 
Iron is an essential nutrient and its importance for the survival of animals, plants and microor-
ganisms is well established. Accordingly to the World Health Organization estimate that about 50% 
of the world’s 5-14 year old children are anemic, as about 50% of the world’s pregnant women. The 
most common symptom of anemia is a general feeling of lack of energy (Beard, 2001). Fe has par-
ticularly relevant roles in neuronal and immune functions (Beard et al., 2003). The human body con-
tains approximately 3 - 5 g of iron and from a diary diet about 15 mg of iron is ingested from which 
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only 1 - 2 mg is absorbed. Iron body distribution is described in figure 1.4.    
A significant fraction of cellular iron is associated with proteins in the form of heme, a prosthet-
ic group composed of protoporphyrin IX and a Fe atom. The Fe insertion into protoporphyrin IX is 
catalyzed by ferrochelatase in the mitochondria. Heme is then exported to the cytosol for incorpora-
tion into hemoproteins. Heme degradation is catalyzed by the microsomal heme oxygenase (HO) 
and the free Fe2+ is reutilized (Ryter and Tyrrell, 2000). This reaction also produces carbon monox-
ide (CO) and biliverdin, which is further converted into the antioxidant bilirubin. The most comum 
mammalian hemoproteins are hemoglobin and myoglobin, oxygen carriers in the erythrocytes or 
muscle cells, respectively. Other hemoproteins are oxygenases, peroxidases or nitric oxide syn-
thases. Heme may also act in electron transfer reactions (such as in cytochromes a, b or c), as a 
substrate activator (in cytochrome oxidase, cytochrome P450, catalase) or as a nitric oxide sensor 
(in guanylate cyclase) (Papanikolaou and Pantopoulos, 2005). 
The most abundant forms of non-heme iron in metaloproteins are iron-sulfer clusters, such as 
2Fe-2S, 3Fe-4S or 4Fe-4S, that may be involved in electron transfer (e.g. the Rieske proteins in 
complex III of the respiratory chain), transcriptional regulation, structural stabilization or catalysis 
(Beinert et al., 1997). Other forms if catalytically active, protein-associated iron may include iron-oxo 
clusters (e.g. ribonuleotide reductase) or mononuclear iron centers (e.g. lipoxygenase and 
cycloxygenase).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 | Iron distribution in the adult human body. A healthy individual absorbs daily 1-2mg of iron 
from the diet, which compensates iron losses by cell desquamation in skin and the intestine. The human 
body contains 3-5 g of iron and the majority of body iron is used within hemoglobin in erythrocytes (60-70%). 
About 20-30% of body iron is stored in hepatocytes and in reticuloendothelial macrophages, as ferritin. The 
remain body iron is localized in myoglobin, cytochromes and iron-containing enzymes Erythropoiesis re-
quires approximately 30 mg iron/day, which is mainly provided by macrophages iron recycling, that ingest 
senescent erythrocytes and release iron to transferrin (Papanikolaou and Pantopoulos, 2005).   
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Two thirds from absorbed iron derives from heme and the remaining fraction is inorganic. Fe 
absorption occurs in the apical membrane if duodenal enterocytes, but the pathway for heme uptake 
is not fully characterized. The mechanism for inorganic iron transport is better established. The low 
pH of the gastric effluent dissolves ingested inorganic iron and facilitates its enzymatic reduction to 
Fe2+ by the ferrireductase Dcytb (Duodenal citochrome b reductase) (McKie et al., 2001). Fe2+ is 
then transported across the membrane by DMT1 (Divalent Metal Transporter 1), also capable of 
transporting Mn2+, Cu2+, Co2+, Zn2+ or Cd2+ (Fleming et al., 1997). In the enterocytes, heme iron is 
liberated by HO and follows the fate of inorganic iron, it is either stored in ferritin or transported 
across the membrane by ferroportin 1 (also known as IREG 1) (Donovan et al., 2000), converted to 
Fe3+ by membrane ferroxidase hephaestin and transferred to plasma transferrin (Tf) (Figure 1.5). 
hCp shares homology with hephaestin and it may also act as a ferroxidase facilitating iron exporta-
tion from enterocytes to Tf (Hellman and Gitlin, 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 | Iron absorption in intestinal epithelium. Representation of iron uptake by enterocytes. 
 
Cell iron homeostasis is shown in figure 1.6. When in plasma Fe-Tf binds to its specific recep-
tor on the cell surface, TfR1 (transferrin receptor 1) and undergoes endocytosis being transported to 
the endosome (Ponka et al., 1998). Fe3+ is then released from Tf by acidification of the endosome to 
pH 5.5, reduced to Fe2+ by Dcytb and transported across the endosomal membrane by DMT1 to 
cytosol. Fe is used for incorporation into iron-containing proteins and the excess is stored into ferri-
tin. The mechanisms of intracellular iron transport to organelles, such as mitochondria, are still not 
fully understood. It seems that there is a ‘labile iron pool’ (LIP) in the cytosol, which remains bound 
to chelates, such as citrate, ATP, AMP or pyrophosphate (Kakhlon and Cabantchik, 2002; Petrat et 
al., 2002; Wang and Pantopoulos, 2011).  
Iron losses in mammals are not regulated. Thus, body iron homeostasis is regulated at the 
level of iron absorption by epithelial cells. Misregulation of this process leads to iron deficiency or 
overload. Iron absorption by enterocytes depends on body iron levels, erythropoiesis levels, hypoxia 
and inflammation (Papanikolaou and Pantopoulos, 2005).   
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Figure 1.6 | Cellular iron metabolism model. TfR1 and ferritin are essential for the control of cellular iron 
homeostasis and their expression is coordinately and reciprocally controlled in response to iron levels by a 
mechanism involving mRNA-protein interactions (Hentze et al., 2004; Pantopoulos, 2004). TfR1 and ferritin 
mRNA contain ‘iron responsive elements’ (IRE) in their 3’ or 5’ UTRs. These motifs of about 30 nucleotides 
fold and form a loop providing a binding site for ‘iron regulatory proteins’ (IRP), which are activated in iron-
starved cells. The IRE-IRP interactions stabilize TfR1 mRNA, which contains five IRE copies, increasing 
TfR1 expression levels and the iron-starved cells acquire more iron from Tf. The IRE-IRP interaction in ferri-
tin mRNAs inhibits their translation and iron-starved cells do not express ferritin, which under these condi-
tions is not necessary. In iron-replete cells IRPs are inactive leading to TfR1 mRNA degradation and ferritin 
mRNA translation. This inhibits iron uptake from transferring and storage and detoxification of excess intra-
cellular iron (Papanikolaou and Pantopoulos, 2005; Wang and Pantopoulos, 2011).  
 
1.2. Cooper and Iron Disorders 
Copper and iron are essential metals and disorders related to these elements may be caused 
by misregulated transport, metabolism or homeostasis. Copper’s biological, functional and structural 
relevance in animals and humans is related to about one dozen cuproenzymes, such as cytochrome 
c oxidase, superoxide dismutase, lysyl oxidase, tyrosinase, ceruloplasmin and dopamine -
monooxygenase (table 1.1). These enzymes are responsible for several important physiological 
reactions. These include mitochondrial transport to support oxidative phosphorylation, removal of 
reactive oxygen species, collagen, elastin and catecholamine biosynthesis, pigmentation, blood 
coagulation, amine oxidation and neuropeptide activation (Danks, 1988). Several cuproenzymes act 
as a ferroxidase converting ferrous to ferric iron and seem to be crucial in iron efflux and homeosta-
sis, as is the case of hCp. Copper deficiency, caused by environmental or genetic factors, leads to 
altered cuproenzyme function. Genetic diseases related to copper homeostasis leading to 
hipocupremia include Wilson disease (WND mutations, protein responsible for copper incorporation 
in hCP), Menkes’ disease (MNK mutations, enzyme responsible for copper absorption by entero-
cytes and copper incorporation into several cuproenzymes) and aceruloplaminemia (hCp mutations, 
cuproenzyme responsible for copper transport and with ferroxidase activity, with a role in iron home-
ostasis and in the oxidation of biogenic amines). Copper has an important role in neurological dis-
turbs. When copper levels are low some alterations occur at neurotransmitters level, such as nore-
pinephrine, serotonin or dopamine, which may explain some behavior changes and development 
disorders that are observed in children. 
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Table 1.1 | Mammal cuproenzymes. 
(Adapted from (de Bie et al., 2007; Prohaska, 2011; Vashchenko and Macgillivray, 2013)) 
 
Common name Putative function Consequences of deficiency 
Amine oxidase Signal transduction, leukocyte adhesion   
Cytochrome c oxidase ATP production, mitochondrial respiration Hypothermia, muscle weakness 
Dopamine--monoxygenase Norepinephrine synthesis Neurological defeats 
Extracellular superoxide 
dismutase  Antioxidant defense Diminished protection against oxidative stress  
Lysyl oxidase Connective tissue formation Laxity of skin and joints 
Peptidylglycine -amidating 
monooxygenase  
Peptide (neuropeptide) amination (matu-
ration) Neuroendocrine defects 
Superoxide  dismutase 1 Superoxide elimination Diminished protection against oxidative stress 
Tyrosinase Pigment formation Hypopigmentation of  hair and skin  
Ferroxidases: 
 
 
Ceruloplasmin Iron/Copper mobilization; iron and amine oxidation 
Decreased circulating copper levels and iron 
deficiency 
GPI-Ceruloplasmin Macrophage iron efflux Neurodegeneration 
Hephaestin 
 
Intestinal iron efflux 
 
Decreased absorption iron levels 
 
 
Iron is a component of several metalloproteins having a crucial role in essential metabolic 
pathways. Its deficit or excess can lead to complications involving organs failure, including neurolog-
ical alterations, and eventually death. Different neuropathologies are involved in iron metabolism. 
Iron deficit may lead to cognitive failure, learning incapability and motor deterioration (Sadrzadeh 
and Saffari, 2004). Brain iron accumulation has been associated with Alzheimer’s disease, Parkin-
son disease and other neurological disorders. Iron is responsible for the oxygen reactive species 
formation leading to cell death, since iron excess is related to toxicity (Halliwell, 1992; Halliwell and 
Gutteridge, 1985). There are also some iron homeostasis alterations that are hereditary, as is the 
case of hemochromatosis associated with HFE gene and its protein, which forms a complex with 
TfR on cell membrane in order to lower the affinity of the receptor to Tf. 
 
1.2.2. Wilson’s disease 
Wilson’s disease (OMIM#277900) is an autosomal recessive disorder caused by the loss-of-
function mutation in the copper transport gene ATP7B or WND. This disorder was first described in 
1912 and results in toxic copper accumulation and multiple organs failure. Mutations in WND protein 
result in impaired excretion of copper into bile and failure to incorporate it into hCp. This leads to 
hepatic copper accumulation and damage, elevated levels of non-ceruloplasmin-bound copper in the 
plasma and copper overload in extrahepatic tissues. Copper accumulation in liver and brain result in 
oxidative stress, hepatic failure and hemolytic anemia (de Bie et al., 2007). Some consider that brain 
copper accumulation results into neurodegeneration with motor symptoms including Parkinsonism, 
dystonia, ataxia, chorea, convulsions and cognitive failure, eventually leading to personality and 
behavior changes, including aggressive behavior and irritability (Attri et al., 2006; Das and Ray, 
2006; de Bie et al., 2007; Taly et al., 2007). Oral copper chelating agents are effective in restoring 
copper homeostasis in many patients with Wilson’s disease (Taly et al., 2007). 
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1.2.3. Menkes’ diseases 
Menkes’ disease (OMIM#309400) is an infantile neurogenetic disorder caused by mutations in 
an X-linked gene, ATP7A or MNK, first described in 1962 as a copper deficiency (Menkes et al., 
1962). MNK mutations result in diminished activity and thus, weak copper intestinal absorption caus-
ing systemic body copper deficit. MNK gene is expressed in muscle, kidney, lung, brain but not in 
the liver. MNK plays a significant role in the development and maintenance of the central nervous 
system, which can be seen by the marked behavioral, neurological, and developmental abnormali-
ties observed in Menkes’ disease patients. Children born with this genetic alteration show develop-
ment delay, bone anomalies, weak and disordered hair growth, neurological alterations and multiple 
organs failure. These symptoms reflect the lack of activity of several cuproproteins, including hCp, 
until death by 3 years of age, depending upon the disease severity. Nowadays, common treatment 
relies on an early diagnostic  and regular copper salt injections (Tumer and Moller, 2010).    
 
1.2.4. Hemochromatosis 
Hemochromatosis (HFE; OMIM#235200) is an autosomal recessive disorder and the most 
prominent iron-related disease in which pathologic symptoms arise from an excessive uptake of 
dietary iron and its deposition in many organs including the brain. The gene involved in hemochro-
matosis is known as HFE and is located at chromosome 6p21.3. The function of HFE protein is to 
complex with the transferrin receptor on the cell membrane and to lower the affinity of the receptor 
for Tf (Feder et al., 1998). The homozygous mutation of the C282Y HFE is responsible for the se-
vere type of this disorder (Feder et al., 1997). The iron deposition is observed in patients mainly after 
40 years old, in the liver, heart, skin and pituitary (Connor, 2003). It is suggested that mutations in 
the hemochromatosis gene HFE that can result in increased iron accumulation in the brain might be 
a risk factor for AD and Parkinsonism associated with hemochromatosis (Dekker et al., 2003; 
Moalem et al., 2000). 
 
1.2.5. Aceruloplasminemia  
Aceruloplasminemia (OMIM#604290) is an autosomal recessive disorder caused by muta-
tions oh hCp gene (Harris et al., 1998; Waggoner et al., 1999). Individuals with this alteration show 
no imunoreactive hCp in plasma (Miyajima et al., 1987). About 40 mutations on hCp gene have 
been identified (frameshift, nonsense, splice site and missense) in 45 different families. About half of 
those mutations lead to the formation of a premature stop codon originating a non-functional C-
terminal truncated protein (Daimon et al., 1995a; Takahashi et al., 1996; Yazaki et al., 1998; 
Yoshida et al., 1995). The molecular analysis of missense mutations have shown different structure-
function relationships  on hCp (Kono and Miyajima, 2006). This disorder is observed in individual 
between 25 and 65 years old and the most common symptoms are diabetes mellitus, glucose intol-
erance, basal ganglia and retinal degeneration and neurodegeneration causing ataxia, dystonia, 
dysarthria and dementia (Harris et al., 1998; Harris et al., 1995; Logan et al., 1994; Miyajima, 2003; 
Morita et al., 1992; Yoshida et al., 2000). This is caused by iron accumulation in organs, including 
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brain, which is what distinguish aceruloplasminemia from other iron disorders, such as HFE, sug-
gesting an important role for hCp in brain iron homeostasis. 
 
1.3. Ceruloplasmin 
Human ceruloplasmin is a 132kDa α2-globulin from human blood serum that binds six copper 
ions. It contains ~95% of serum copper (Harris et al., 1998) and was first described in 1944 by 
Holmberg (Holmberg, 1944). hCp was latter characterized in 1948 as a cuproprotein (Holmberg and 
Laurell, 1948; Mittal et al., 2003). In 1952, Scheinberg and Gitlin observed a decreased concentra-
tion of plasma hCp in patients with Wilson’s disease (Aldred et al., 1987; Scheinberg and Gitlin, 
1952). Now it is known that is not hCp concentration, but its enzymatic activity which drops as the 
protein is synthesized in liver predominantly in the apo-form, as there is no copper incorporation by 
WND.  
Soon after, the hCp was described as being related to neurodegenerative processes in hu-
mans. In 1966, Friden demonstrated that hCp is a ferroxidase  suggesting a role for ceruloplasmin in 
iron homeostasis (Osaki et al., 1966). In the 1970’s indirect indications concerning possible involve-
ment of hCp in oxidation of epinephrine and serotonin in the CNS (Barrass and Coult, 1972; Barrass 
et al., 1972; Barrass et al., 1973; Barrass et al., 1974) were described and the protein was detected 
in the brain (Linder and Moor, 1977). Later the details of its synthesis in glial cells were described 
(Klomp and Gitlin, 1996; Mollgard et al., 1988; Patel and David, 1997; Patel et al., 2000).  
 In 1984, Putnam determined the complete amino acid sequence of hCp, revealing the single-
chain structure of this molecule (Takahashi et al., 1984). Isolation and characterization of hCp cDNA 
confirmed the amino acid sequence obtained by protein chemistry and demonstrated abundant ex-
pression of the ceruloplasmin gene in the liver (Koschinsky et al., 1986; Yang et al., 1986). hCp was 
identified as an essential protein in 1995 with the identification of patients with aceruloplasminemia 
(Harris et al., 1995).  
It is thought that hCp plays an important role in the metabolism and development of nervous 
tissue (Friedenberg and Brighton, 1966), as its deficiency, its impaired function, or the failure of cop-
per metabolism can lead to severe neurodegenerative diseases as Parkinson’s disease, Alzheimer’s 
disease or aceruloplasminemia (Castellani et al., 1999; Kaneko et al., 2002b; Loeffler et al., 1996). 
 
1.3.1. Gene structure and expression 
 hCp gene is localized to chromosome 3q23-q24 encoded in 20 exons encompassing approx-
imately 65kb (Daimon et al., 1995b; Koschinsky et al., 1987; Koschinsky et al., 1986). In hepato-
cytes, the hCp gene is expressed as two transcripts of 3.7 and 4.2 Kb, which arise from alternative 
polyadenylation sites within the 3’ untranslated region (Koschinsky et al., 1986; Yang et al., 1986).  
Expression of these transcripts in the liver results in the 1046 amino acid protein detected in serum. 
hCp precursor has 1065 aa, and its first 19 residues encode for a signal peptide which is cleaved 
arising a 132 kDa serum protein with 6 N-glycosylation sites with 7-8% carbohydrate content 
(Koschinsky et al., 1986). hCp has a high homology to type-A domains of clotting factors V and VIII 
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(Patel and David, 1997). hCp is an acute phase reactant and the serum concentration increases 
during processes of inflammation, infection or trauma as a result of increased gene transcription in 
hepatocytes mediated by the inflammatory cytokines (Gitlin, 1988). 
Serum hCp is predominantly synthesized in the liver, but extrahepatic gene expression has 
been described in brain, spleen, lung and testis (Aldred et al., 1987; Fleming and Gitlin, 1990; Klomp 
et al., 1996). In the CNS, hCp is expressed in neurons and astroglial cells, e.g. cerebral 
microvascular network involving dopaminergic neurons in substantia nigra (Klomp and Gitlin, 1996; 
Kuhlow et al., 2003; Loeffler et al., 2001). In astrocytes, and Sertoli cells, hCp is membrane an-
chored by glycosylphosphatidylinositol (GPI), which is caused by alternative splicing of exons 19 and 
20 in hCp gene (Fortna et al., 1999; Mittal et al., 2003; Patel and David, 1997; Patel et al., 2000; 
Salzer et al., 1998). As a result, the latest 5 C-terminal aa found in serum hCp are replaced by a 30 
aa stretch in GPI-hCp. This isoform seem to have an important role in iron oxidation and mobilization 
across blood brain barrier, which in cooperation with the iron exporter protein IREG1 provides the Fe 
efflux from astrocytes (Klibanoff et al., 1966; Trader and Frieden, 1966). The plasma hCp cannot 
cross the blood brain barrier. The insufficiency of hCp synthesis or its decreased activity in the cells 
of the CNS is regarded as one of the mechanisms underlying the development of a number of neu-
rodegenerative disorders (Connor et al., 1993; Kuhlow et al., 2003; Qian and Wang, 1998; Snaedal 
et al., 1998; Torsdottir et al., 2001; Torsdottir et al., 1999). Both hCp isoforms are synthesized with 
six atoms of copper incorporated during biosynthesis in the Golgi complex (Harris, 2003; Holmberg 
and Laurell, 1948; Miyajima et al., 2003). Serum hCp has a half-life of 5.5 days with little or no ex-
change of hCp-bound copper after synthesis. Although copper has no effect on the rate of synthesis 
or secretion of hCp, failure to incorporate Cu during synthesis results in apo-hCp, an unstable pro-
tein with no ferroxidase activity (Kaneko et al., 2002b; Miyajima et al., 2002a; Perez-Aguilar, 2002). 
This apoprotein is rapidly catabolized in 5 hours (Nittis and Gitlin, 2002).  
 
1.3.2. Metabolism 
As referred, hCp is implicated in Cu and Fe metabolism. Fe is absorbed by epithelial cells in 
duodena and released into blood stream (Harris, 2002). hCp is involved in iron transport across the 
cell membrane. This protein oxidizes ferrous iron and incorporates the ferric form into apotransferrin 
(Kaneko et al., 2002a; Miyajima et al., 2002b). It is known that, at physiological pH, Fe2+ is autox-
idized to Fe3+ with no need for a specific catalyst (Hellman et al., 2002). However, this non-
enzymatic oxidation has a high probability of trigger reactions of Fenton and/or Haber-Weiss chem-
istry with the production of oxygen radicals. The role of hCp might be an efficient control of the level 
of ferrous iron oxidation without the production of hydrogen peroxide as an end product. 
Cu is absorbed in duodena and transported to liver by hCtr1 and stored in hepatocytes 
(Miyajima, 2000a, b). Once in the cell, Cu might be i) stored in Cu-thioneine form, ii) transported by 
Ccs to SOD, iii) delivered into mitochondria by cox17 or iv) transported by HAH1 to WND ATPase 
localized in the trans-Golgi network. WND ATPase helps to Cu incorporation into hCp (Kohno et al., 
2000). hCp carries about 90% of the total copper in human plasma but its synthesis is not depend-
ent on Cu levels (e.g. Wilson disease). It is also thought to provide Cu2+ ions for other proteins. The 
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copper stored into hepatocytes can generate hydroxyl radicals caused by the redox cycle between 
Cu1+ e Cu2+ which may cause damage in DNA, proteins, lipids and cell intoxication, leading to cir-
rhosis. Cu can also accumulate in the brain causing neurodegeneration with hyperkinesis, dysarthria 
and dementia. 
 
1.3.3. Role and function 
Ceruloplasmin is a metalloenzyme belonging to the iron (II) oxygen oxidoreductase class, EC 
1.16.3.1, and to the multicopper oxidases family, also known as blue oxidases.  
In vitro studies showed that hCp is capable of catalyze the oxidation of different substrates:  
i) Fe2+, the substrate with the higher Vm and lower Km; 
ii) a group of bifunctional amines and phenols (including biogenic amines, epinephrine and 
serotonin (5-hydroxy-indole family) and phenothiazines) which do not depend on iron for its activity; 
iii) pseudo-substrates including several reducing agents capable of reducing Fe3+ or partially 
oxidize the intermediaries in ii) (Frieden and Hsieh, 1976b). 
So, hCp has ferroxidase activity, oxidizing Fe2+ to Fe3+ and incorporating it into apotransferrin 
(Osaki et al., 1966, 1971) and has an essential role in iron metabolism (Attieh et al., 1999; Harris et 
al., 1995; Lahey et al., 1952; Vulpe et al., 1999). It is also an acute phase reactant having antioxi-
dant properties and being capable of remove H2O2 (Giurgea et al., 2005; Gutteridge, 1978). Howev-
er, studies show that this protein can also act as a prooxidant promoting LDL (low density protein) 
oxidation (Mukhopadhyay et al., 1996; Mukhopadhyay et al., 1997). It is known that chloride inhibits 
hCp ferroxidase activity at pH 5.5, but it is thought that at neutral pH chloride might enhance the 
oxidase activity of hCp and this enzyme might even exhibits an important role in the oxidation of 
several substrates present in the serum plasma (Musci et al., 1995). A group showed that such ani-
ons as chloride or azide increase the aminoxidase activity of hCp and that this effect is observed 
with non iron substrates, while Fe2+ oxidation remains unaffected (Musci et al., 1999). 
Human ceruloplasmin functions include: 
a) Ferroxidase activity, eliminating free iron in the plasma, protecting blood and lipidic mem-
branes from peroxidative damage (antioxidant), and/or mobilize iron from cells for transporting 
via Tf; 
b) Aminoxidase activity for controlling the levels of biogenic amines in the plasma, spine cord 
and interstitial fluids; 
c) Copper transport for metal distribution for extra hepatic tissues. 
 
1.3.4. Functional mechanism 
Multicopper oxidases are characterized by the presence of three types of spectroscopically 
distinct copper sites (Messerschmidt and Huber, 1990). These are usually referred as type I, II or III 
copper centers and can be characterized in the following way (Holwerda et al., 1976; Malmstrom, 
1982):  
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a) Type I: a single Cu2+ coordinated by 2 histdine residues and a cysteine residue, in which 
thiolate ion act as an electron donor, and a variable axial ligand, in a trigonal planar structure. 
Those proteins with type I copper center show high redox potentials (>250mV) and a strong 
absorption at 600nm, due to S Cu charge transfer conferring a blue color and the name ‘blue 
oxidases’. This copper center type has a detectable EPR (electron paramagnetic resonance) 
spectrum (Sakurai and Kataoka, 2007; Yoshida et al., 1995). 
b) Type II: a single Cu2+ coordinated by N/NO in a tetragonal square-planar configuration. EPR 
parameters are detectable but those ions have no specific absorption and no blue color.  
c) Typo III: two antiferromagnetically (i.e. spin pairing) coupled copper ions (Cu2+-Cu2+), each 
one coordinated by 3 histidine residues. EPR parameters are not detectable but those ions 
absorb strongly at 330nm. 
 
Generally, multicopper oxidases are promiscuous with regards to their reducing substrates 
and are capable of performing various functions in different species. These oxidases catalyze the 
four-electron reduction of dioxygen to two molecules of water, with the concomitant reduction of one 
electron from the substrate. The type I Cu2+ is the primary electron acceptor. This electron cannot be 
passed directly to the type III center before type II Cu2+ is reduced, because the type III center acts 
as a 2 electrons cooperative acceptor. The reduction of the two type III Cu2+ occurs by an 
intramolecular transfer of the 2 electrons from type I and type II reduced centers, and then to the 
oxygen moiety (Malmstrom, 1982). The aa sequences responsible for the copper binding are highly 
conserved between the multicopper oxidases, but the substrates, number of type I copper centers 
and the intramolecular mechanisms for electronic transfer vary between proteins (Bento et al., 
2007). As exemples of this family members there is the lacase, the ascorbate oxidase, Fet3 and 
hephaestin, a hCp homologue needed to the iron efflux from placenta and enterocytes (Marques et 
al., 2012; Vashchenko and Macgillivray, 2013). 
Ceruloplasmin, the only blue copper oxidase found in humans, has 3 type I cooper centers, 
which conferee a intense blue color to this blue oxidase, and a type II Cu2+ coordinated by 2 nitrate 
atoms close to the 2 antiferromagnetically coupled type III Cu2+. The type II and type III copper ions 
form a trinuclear Cu2+ cluster where the oxygen binds during the catalytic cycle and gets reduced to 
water (Miyajima et al., 1998). The hCp X-ray tridimensional structure confirmed the presence of this 
trinuclear cluster and the identity of the residues involved in the cooper binding and stabilization 
(Bento et al., 2007; Jeong and David, 2003).  
 
1.3.5. Tridimensional structure 
Ascorbate oxidase X-ray crystallography structure (D'Andrea et al., 1989; Malmstrom, 1982) 
and by sequence analysis allowed us to understand that hCp has a six-domain structure involving a 
threefold repeat and that domains 2, 4 and 6 should bind mononuclear coppers, with a possible 
trinuclear site between domains 1 and 6 (Messerschmidt and Huber, 1990).  
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Later, the overall organization of ceruloplasmin and the nature of the 6 copper binding sites 
was determined by X-ray crystallography at a resolution of 3.1 Å (Zaitseva et al., 1996) and more 
recently at 2.8 Å (Bento et al., 2007) (figure 1.7 and table 1.2). The six cupredoxin-like domains are 
arranged in triangular array and each of them comprises a -barrel. Cupredoxins are single domain 
β-barrel proteins that bind a mononuclear type I copper redox site and are involved in inter-
molecular electron transfer reactions (figure 1.8) (Roberts et al., 2002). A -barrel is a large beta-
sheet that twists and coils to form a closed structure in which the first strand is hydrogen bonded to 
the last. -strands in -barrels are typically arranged in an antiparallel way.  
hCp has five disulphide bridges located in domains 1–5 and serve to anchor the last strand of 
each domain. The C-terminal strand in domain 6 is not anchored to domain 6 through a disulphide 
bridge. Ceruloplasmin is readily cleaved into three fragments with molecular weights of 67, 50 and 
19 kDa respectively. The 19-kDa fragment corresponds almost exactly to domain 6 (Takahashi et 
al., 1983; Zaitseva et al., 1996). hCp shows heterogeneity with respect to its carbohydrate moieties, 
but has at least 3 glycan chains ending in sialic acid (Bento et al., 2007; Endo et al., 1982).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 | A view of the human ceruloplasmin X-ray crystallography structure. Domains 1, 2, 3, 4, 5 
and 6 in green, red, yellow, purple, orange and pink, respectively, and the locations of the metal binding 
sites for Cu2+ as blue spheres and O2 as light-blue spheres. The figures were prepared with the PyMOL pro-
gram (http://www.pymol.org) using the Research Collaboratory for Structural Bioinformatics Protein Data 
Base protein code 2J5W (Bento et al., 2007). 
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Figure 1.8 | hCp cupredoxin-like domain 1. The trinuclear copper cluster (Cu2+ as orange spheres) and 
the glucan chain at N119 residue are shown (Bento et al., 2007). 
 
1.3.5.1. Copper binding sites 
As expected, three copper atoms bind in domains 2, 4 and 6 as mononuclear centers, and the 
remaining 3 form a trinuclear cluster between domains 1 and 6 (figure 1.9). The disposition if the 
trinuclear cluster and the nearest mononuclear copper, that in domain 6 is closely similar to that 
found in the subunit of ascorbate oxidase (Messerschmidt et al., 1989), might support the hCp oxi-
dase function.  
 
 
 
 
 
 
 
Figure 1.9 | Schematic diagram of hCp structure. Domains 1-6 and (●) copper centers 
(Zaitseva et al., 1996). 
 
1.3.5.1.1. Mononuclear type I copper centres  
One type I site is in the C-terminal domain (domain 6) coupled to the trinuclear cluster via a 
CysHis pathway and the other 2 type I Cu sites are found in domains 4 and 2 (Zaitseva et al., 1996). 
The type I Cu sites in domains 4 and 6 are both redox-active, and both have a divalent metal ion 
binding (M2+) site adjacent to them and a trivalent metal ion biding site (M3+) located above this and 
closer to surface (Lindley et al., 1997). This suggested that both may be involved in the ferroxidase 
activity of hCp and was latter supported by structural data (Bento et al., 2007). It seems that only the 
type I copper in domain 6 at a distance of 12–13 Å from the trinuclear cluster is absolutely necessary 
for hCp catalytic action (Messerschmidt et al., 1992). The distances between the copper ions is 
around 18 Å which is well within the range of effective electron transfer (figure 1.10) (Lindley et al., 
1997; Patel et al., 2000) and it is possible that the copper ions in domains 2 and 4 could provide a 
slower route of electron transfer, allowing the oxidation of more than one substrate molecule at a 
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time. This could accomplish a more effective transfer of four electrons to the dioxygen molecule from 
the reducing substrate. The exact role of copper ion in domain 2 is yet not known. The type I Cu site  
in domain 2 differs from the others in lacking an axial methionine being replaced by an aliphatic 
leucine residue (Bento et al., 2007; Salzer et al., 1998). Metal soaking or organic substrate-soaking 
experiments showed no reducing substrates binding to domain 2 (Bento et al., 2007). Some studies 
showed that the type I copper in domain 2 remains permanently reduced, at least in part due to a 
high reduction potential, and since this site cannot be oxidized it is not catalytically relevant and is 
likely a vestige of gene duplication (Patel and David, 1997; Patel et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 | Copper centers in hCp. Separation of the copper atoms in the trinuclear centre, the distance 
of this cluster from the nearest mononuclear copper in domain 6, and the separation between the mononu-
clear copper atoms. Copper binding histidine residues are represented in the diagram (Zaitseva et al., 1996). 
 
1.3.5.1.2. Trinuclear copper centre  
The trinuclear copper center has a type II and two type III copper cations with a dioxygen 
moiety bound (figure 1.11). The acidic residue E1032 may be necessary for the initial protonation of 
the dioxygen molecule. The type II copper seems to have two configurations, one linked to an oxy-
gen moiety and the other to a water moiety, with a hydrogen bond formed with the hydroxyl group of 
Y107, in either case. 
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Figure 1.11 | Trinuclear copper centre. Located between domains 1 and 6 with a water molecule attached 
to the type II copper and a diatomic species, assumed to be dioxygen, placed within the type III cluster 
(Bento et al., 2007). 
 
1.3.5.2. Iron binding sites 
Structural data indicates that the iron-binding sites seem to be in domains 4 and 6 of the hCp 
structure, which seems to be consistent with earlier biochemical data suggesting two iron-binding 
sites in the enzyme (Frieden and Hsieh, 1976a). The access to these sites is limited to relatively 
small substrates by three large protuberances at the top of the hCp molecule (Bento et al., 2007). It 
is not yet fully understood and there is no published structural data but, both Fe2+ and Fe3+ seem to 
bind to sites near the outside of the protein. The Fe2+ releases an electron to the nearest mononu-
clear copper and then translocate to the other site with E597 and E935 in domains 4 and 6, respec-
tively, playing key roles in the translocation process (figure 1.12). At this site the ferric iron would be 
available for collection, for example, by serum transferrin (Bento et al., 2007).  
 
 
 
 
 
 
 
 
 
Figure 1.12 | Cation binding to ceruloplasmin by Fe2+. The red electron density is negative indicating loss 
of the labile Cu2+ cations. The blue density is positive indicating acquisition of cations at the holding sites 
(Lindley et al., 1997).  
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Table 1.2 | hCp sequence features (Bento et al., 2007; Lindley et al., 1997; Zaitseva et al., 1996). 
Feature Positions (bp) Length (bp) Description 
Molecule processing    
Signal peptide 1 – 19 19 (Takahashi et al., 1984) 
Ceruloplasmin chain 20 - 1065 1046  
Domains    
1 20 – 211 191  
2 212 – 359 147  
3 360 – 572 212  
4 573 – 722 149  
5 723 – 903 180  
6 904 – 1065 161  
Sites    
Metal binding H120 1 Type 2 Copper 1 – Domain 1 
Metal binding H122 1 Type 3 Copper 2 – Domain 1 
Metal binding H180 1 Type 3 Copper 2 – Domain 1 
Metal binding H182 1 Type 3 Copper 3 – Domain 1 
Metal binding H295 1 Type 1 Copper 4 – Domain 2 
Metal binding C338 1 Type 1 Copper 4 – Domain 2 
Metal binding H343 1 Type 1 Copper 4 – Domain 2 
Metal binding H656 1 Type 1 Copper 5 – Domain 4 
Metal binding C699 1 Type 1 Copper 5 – Domain 4 
Metal binding H704 1 Type 1 Copper 5 – Domain 4 
Metal binding M709 1 Type 1 Copper 5 – Domain 4 
Metal binding H994 1 Type 1 Copper 6 – Domain 6 
Metal binding H997 1 Type 2 Copper 1 – Domain 6 
Metal binding H999 1 Type 3 Copper 3 – Domain 6 
Metal binding H1039 1 Type 3 Copper 3 – Domain 6 
Metal binding M1040 1 Type 1 Copper 6 – Domain 6 
Metal binding H1041 1 Type 3 Copper 2 – Domain 6 
Metal binding H1045 1 Type 1 Copper 6 – Domain 6 
Metal binding M1050 1 Type 1 Copper 6 – Domain 6 
Amino acid modifications    
Glycosylation 138 1 N-linked 
Glycosylation 358 1 N-linked 
Glycosylation 397 1 N-linked 
Glycosylation 588 1 N-linked 
Glycosylation 762 1 N-linked 
Glycosylation 926 1 N-linked 
Disulfide bond 174 ↔ 200   
Disulfide bond 276 ↔ 357   
Disulfide bond 534 ↔ 560   
Disulfide bond 637 ↔ 718   
Disulfide bond 874 ↔ 900   
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1.4. Ceruloplasmin and neurodegeneration 
Both GPI-anchored and secreted hCp enable IREG 1 to conduct the efflux of iron from cells of 
the CNS (Jeong and David, 2003). All these notions tend to indicate the important role of Cp in iron 
metabolism and this concept has been strengthened by some recent findings, including the one 
described for severe disorders of iron metabolism in aceruloplasminemia. It has been suggested that 
hCp catalyzed oxidation of biogenic amines, such as epinephrine, norepinephrine and serotonin, 
may be of importance in regulating the level of these stress hormones in the bloodstream and even-
tually in those areas of the brain where they act as neurotransmitters. Thus, hCp by its effect on the 
lifetime of biogenic amines in the bloodstream could play an important role in the regulation of brain 
chemistry necessary for mental function. It is also important to understand if hCp is able to enhance 
the oxidation of 6-hydroxydopamine (Medda et al., 1996), an intermediate product on the way to the 
formation of dopamine-melanin (Chapman et al., 1970). Oxidation of 6-hydroxydopamine by hCp 
does not result in H2O2 production. It seems likely that Cp might be the enzyme that controls or par-
ticipates in controlling catecholamine oxidation in the brain and that its deficiency in cerebral struc-
tures underlies Parkinson’s disease and perhaps other neurodegenerative syndromes (Floris et al., 
2000). Enhanced oxidation of dopamine by hCp has been invoked to explain the lower dopamine 
levels found in Parkinson’s disease. 
 
1.4.1. Ceruloplasmin and Alzheimer’s and Parkinson’s diseases  
Alzheimer disease (AD; OMIM#104300) is the most common disease associated to degenera-
tive dementia with gradual deterioration of memory, behaviour, cognition and ability to perform sim-
ple tasks, due to cortical neurons death in the brain. Brain high metal levels, such as copper or iron, 
have been associated with AD (Altamura and Muckenthaler, 2009; Lovell et al., 1998; Roos et al., 
2006). Amyloid precursor protein (APP) is a glycosylated protein of unknown biological function that 
is uniformly found in the membranes of cells in the body, but predominantly in the brain. Once in the 
CNS, this protein is cleaved into several peptides that might possible have some protecting effect on 
the integrity of synaptic structures. Most of these cleavage products are soluble and never accumu-
late. However, in AD there is a less soluble but more abundant variant, the -amyloid peptide which 
aggregates forming plates that are found in the dysfunctional brain regions (Zerbinatti et al., 2004). 
Increased levels of copper, iron, zinc or aluminum accumulates in the plates. The -amyloid peptide 
has copper and iron binding domains which interact with the peptide leading to its aggregation and 
oxidative stress in AD (Desai and Kaler, 2008; Dingwall, 2007; Ha et al., 2007; Sadrzadeh and 
Saffari, 2004; Taylor et al., 2002). The iron content in the AD brain is normally not increased and the 
abnormal iron accumulation must be evidence of a dysfunctional status of iron in the brain. This may 
indicate a dysfunctional ferritin increasing the oxidative stress and an important role of hCp in pro-
tecting the CNS from iron-mediated free radical injury (Patel et al., 2002). However, the hCp concen-
tration was found normal in AD patients but its activity was lowered and the free copper in plasma 
was increased. This indicates failing in incorporating copper into hCp. Moreover, low amount of cop-
per in AD brains may result in defective synthesis of hCp and other copper enzymes (Johannesson 
et al., 2012).  
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Parkinson’s disease (PD; OMIM#168600) is a common progressive neurodegenerative motor 
pathology first described by James Parkinson in 1817. It is characterized by shaking, rigidity, slow-
ness of movement, difficulty with walking and loss of equilibrium. Later, thinking and behavioral 
problems may arise, with dementia commonly occurring in the advanced stages of the disease 
(Gaggelli et al., 2006). This phenotype is associated dopaminergic neurons death in the substantia 
nigra and accumulation of Lewy bodies associated with mutations in -synnuclein, a protein which is 
expressed in CNS with uncertain function (Rasia et al., 2005). This protein binds iron and copper 
and aggregates leading to the production of ROS and cell death at substantia nigra which causes 
motor dysfunction (Rasia et al., 2005; Sadrzadeh and Saffari, 2004). In PD patients there is loss of 
ferritin and iron is increased in the brain and hCp activity is lowered (Jin et al., 2011). It is possible 
that hCp variants may be associated with iron accumulation in the substantia nigra in PD patients. 
The oxidative activity of hCp is involved in the oxidation of catecholamines, as dopamine and epi-
nephrine, in neurons. The resulting product is neuromelanin which binds iron keeping the levels of 
Fe2+ low in the midbrain. In PD the dying neurons release neuromelanin with is digested by microglia 
and the iron is released increasing the oxidative stress. hCp might have an important role in protect-
ing neurons and preventing tissue damage and PD progression (Kristinsson et al., 2012). On the 
other hand enhanced oxidation of dopamine by hCp has been claimed to explain the lower dopa-
mine levels found in Parkinson’s disease.  
 
1.4.2. Ceruloplasmin and neurotransmitters  
As described before, biogenic amines oxidation by hCp seems to have an important role in 
hormones and neurotransmitters levels regulation in brain and bloodstream. hCp can use as sub-
strates epinephrine, norepinephrine, dopamine, dopa and serotonin (figure 1.13). Zaitsev and col-
leagues showed that these substrates seem to bind at the same place in the hCp molecule, in do-
main 6, 9.7 Å distant from the type I copper site (Zaitsev et al., 1999). Apparently, residue D1025 is 
one of the ligands which bind the labile copper together with H940, E935 and E272. It is proposed 
that the amine binds to any labile copper, an electron is transferred to the domain 6 copper causing 
oxidation of the substrate, and eventual reduction of oxygen at the trinuclear copper site. 
Figure 1.13 | Oxidation reactions and products of biogenic amines (Zaitsev et al., 1999). 
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1.5. X-ray crystallography 
The aim of X-ray crystallography is to obtain a three dimensional molecular structure from a 
crystal. A purified sample at high concentration is crystallized and then the crystals are exposed to 
an X-ray beam. The resulting diffraction patterns are then processed, initially to yield information 
about the crystal packing symmetry and the size of the repeating unit that forms the crystal. This is 
obtained from the pattern of the diffraction spots. The intensities of the spots can be used to deter-
mine the “structure factors” from which a map of the electron density can be calculated. Several 
methods can be used to improve the quality of the map until it is of sufficient clarity to permit the 
building of the molecular structure using the protein sequence. The resulting structure is then refined 
to fit the map more accurately and to adopt a thermodynamically favored conformation. 
The x-rays were first discovered in 1895 by Wilhelm Roentgen and in 1912, Max von Laue, 
Walter Friedrich and Paul Knipping showed that X-rays are diffracted by crystals forming a pattern 
(Eckert, 2012). In 1914, William Henry Bragg and is son William Lawrence Bragg analyzed a crystal 
structure by means of X-rays, showing that the scattering of X-rays could be represented as a reflec-
tion by successive planes of atoms within a crystal, which can be used to determine relative posi-
tions of atoms within a crystal, and so the molecular structure (Bragg’s law).  
X-ray crystallography is the most powerful method to obtain a macromolecular structure. 
Structural crystallography is based on the scattering of X-rays by the electrons in the molecules of 
the analyzed sample. The interference of the scattered waves can be constructive or destructive and 
is called diffraction. For diffraction to be observed, the wavelength () of radiation must be about 
equal to the distances between the atoms (0 – 5Å; 1Å = 0.1 nm) which corresponds to the X-rays 
wavelength. The pattern of diffracted X-rays is useful to obtain the orientation of atoms in space. 
This pattern can only be achieved if there is repetition of the sample macromolecule in order to am-
plify and enhance the scattering of the X-radiation. This is why crystals are needed. A crystal is a 
solid with regular 3D ordering. The regular repeat and high similarity of the structural motifs forming 
the individual unit cell allows the enhancement of the scattering of X-radiation in selected direction 
and extinguish completely in others (figure 1.14).     
 
 
 
 
 
 
Figure 1.14 | How X-rays interact with the atoms in a crystal (from wikimedia). 
 
1.5.1. Protein crystallization  
For protein crystallography, protein crystals are needed and for that a purified sample at high 
concentration must be available for crystallization. One of the limiting steps of protein crystallog-
raphy is the growth of good quality protein crystals. The principle of crystallization is to take a solu-
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tion of the sample at high concentration and induce it to come out of solution in an ordered way to 
form a crystal (Gernert et al., 1988). However, if it happens too fast precipitation will occur. Unfortu-
nately, some proteins are apparently not crystallizable. Some variables must be taken in account 
when trying to crystallize a protein: the precipitant, its concentration, the buffer, its pH, the tempera-
ture, the protein concentration, the inclusion of additives and the crystallization technique. The inter-
action of multiple variables and resulting solubility with respect to crystallization outcomes are repre-
sented using a phase diagram (figure 1.15). The two dimensional space diagram is a representation 
of the phase of a protein regarding its concentrations and the crystallizing agent that can be the pH, 
the buffer, the temperature, etc. The diagram can be divided into zones defined as undersaturated, 
saturated, metastable, labile, and precipitation. Undersaturated solutions will remain in a liquid 
phase. Saturation is a solution state where a crystal, if present, would remain in equilibrium with the 
surrounding solution. If a crystal is in a clear metastable solution (supersaturated), the protein would 
add to the surface of the growing crystal until the solution reached saturation. The two zones most 
relevant to crystallization are the metastable and labile zones. The labile zone is highly supersatu-
rated and the protein undergoes spontaneous, homogeneous nucleation. Once the nuclei form, the 
level of supersaturation can decrease to the metastable zone that will not produce additional crystal 
nuclei but will support crystal growth. The precipitation zone, which is too supersaturated to support 
ordered aggregation, results in amorphous precipitate (Luft et al., 2011). 
Initially, the experiments start based on a trial and error procedure and based on the solubility 
diagram proceed until crystals appear. For this there are commercially available crystal screens 
which cover as wide a range as possible of the variables like the precipitant, buffer, pH and salt. 
These screens can be set upped using the different crystallization techniques, being the most com-
mon the sitting drop vapour diffusion, hanging drop vapour diffusion and microbatch (figure 1.16). 
Also several techniques can be used to improve crystal size and quality, as seeding, alteration of 
protein concentration, or precipitant concentration, addition of additives or even alteration of the 
temperature. It is also important to verify if the crystals are protein crystals and not salt crystals, this 
can be performed by SDS-PAGE analysis, staining, UV exposure or X-ray diffraction exposure. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15 | Schematic illustration of a typical crystallization phase diagram (Luft et al., 2011). 
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Figure 1.16 | Vapour-diffusion crystallization methods. A, hanging drop; B, sitting drop. 
  
1.5.2. X-ray diffraction analysis 
The X-rays can be generated from accelerating electron in a synchrotron storage ring, where 
a single X-ray wavelength is selected by absorption of unwanted wavelengths (monochromation), or 
from electrons striking a copper anode in a diffractometer, where one predominant wavelength is 
produced. The X-rays must be focused into a beam where the crystal will be mounted in. The crys-
tals can be mounted in a capillary tube at room temperature, or mounted frozen in a small loop in a 
stream of liquid nitrogen at 100 K (Hope, 1990). The distance from the crystal to the detector is cal-
culated and adjusted to allow for collection of diffracted spots, usually up to a maximum of 1.5–3.0 Å 
resolution. The first diffraction image from a crystal showing the diffraction map (figure 1.17) gives us 
visually already some information by detecting well ordered spots. Spots beyond 3 Å are rather re-
quired, since a carbon–carbon bond is approximately 1.5 Å but a resolution of close to 3 Å is suffi-
cient to be able to detect  the amino acid side chains in the electron density map (Smyth and Martin, 
2000). It is necessary that the diffraction has sufficient resolution to make structure determination to 
near atomic detail possible. Then the unit cell dimensions, the crystals system and the space group 
must be determined. The unit cell is the smallest repeating unit that makes up the crystal. Its dimen-
sions are given as three lengths: a, b, and c; and three angles: , , and  (which are usually omitted 
if 90°). The shape of the unit cell determines the crystal system (table 1.2). The space group is pro-
vided by the symmetry of the diffraction pattern, allowing the packing of the molecules into the crys-
tal lattice to be determined.  
 
Table 1.3 | Crystal systems. Adapted from (Smyth and Martin, 2000). 
Crystal system Axes  Interaxial angles 
Triclinic a ≠ b ≠ c ≠≠≠°
Monoclinic a ≠ b ≠ c ==° ≠  
Orthorhombic a ≠ b ≠ c ===° 
Tetragonal a = b ≠ c ===° 
Trigonal a = b ≠ c ==°=° 
Hexagonal a = b ≠ c ==°=° 
Cubic a = b = c ===° 
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Figure 1.17 | An X-ray diffraction pattern of a crystallized enzyme. The pattern of spots (reflections), 
formed from the constructive interference of X-rays passing through a crystals, and the relative strength of 
each spot (intensities) can be used to determine the structure of the enzyme (from wikipedia). 
 
1.5.3. The phase problem 
To calculate electron densities from a diffraction experiment is necessary to know the indices 
of a reflection, the intensity of the reflections and the phase angles of the reflection. The first two can 
be determined directly from the experiment. So, the intensity of a diffracted spot is a function of the 
amplitude of the reflection and the phase angle between the diffracted waves. The indices of a re-
flection are determined by the symmetry of the crystal and the intensities can be measured by detec-
tion devices. The phase angles cannot be determined directly. From the amplitude and the phase 
the structure factor can be determined and the arrangement of the atoms in the unit cell can be cal-
culated. The most frequently used methods are multiple isomorphous replacement and molecular 
replacement. Once amplitudes and phases are determined the structure factors can be calculate 
and the resulting electron density map will form the 3D map into which the protein structure will be 
built. 
 
1.5.3.1. Multiple Isomorphous replacement 
 This method is used when no closely related structure is available and requires a data sets 
from the native protein crystal and another from the protein crystals with attached heavy atoms 
(Watenpaugh, 1985). The protein crystals can be soaked in a solution of mercury, platinum, gold to 
incorporate a few atoms into the protein molecule without altering to much either the conformation of 
the protein or the unit cell dimensions. When compared the differences between the data sets re-
sults from the heavy atoms and their positions in the protein molecules can be determined. Refine-
ment of the heavy atom parameters is achieved and can be used to start the determination of the 
protein phase angles, which together with the amplitudes can be used to calculate the structure fac-
tors, used in the refinement procedure. 
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1.5.3.2. Molecular replacement 
This method is used when a very closely related protein structure is available either if there is 
close homology of the amino acid sequence or if two structures are expected to be similar 
(Rossmann, 1990). It involves the crystallographic calculation in reverse, structure factors from the 
known coordinate file and then using the phases from the known model structure and applying it to 
the new data set to calculate the new structure factor. Before the phases can be applied, the struc-
tural model must be placed into the unit cell in exactly the same position and orientation as the new 
protein molecule. The phases from the model structure factors may then be applied and with the 
new amplitudes a new set of structure factors can be calculated and refined. 
 
 
1.6. Objective 
The aim of this present work is to achieve human ceruloplasmin good diffracting crystals in 
order to solve its tri-dimensional structure at a higher resolution than what is already published. A 
higher resolution structure allows us to unveil some protein residues previously not detected be-
cause of lower resolution data. Also a higher resolution can unveil copper and iron labile binding 
sites. Thus, several methods will be applied to obtain better stabilized and soluble ceruloplasmin, 
more prone to crystallize. 
In this study is also essential to obtain crystals of human ceruloplasmin in combination with 
epinephrine, serotonin, dopamine and/or L-dopa. As ceruloplasmin has an important aminoxidase 
activity, being responsible for the regulation of hormones in blood and brain and for the brain home-
ostasis, it is important to understand in what way this protein can be involved in some neurodegen-
erative disorders, as Alzheimer’s or Parkinson’s diseases. The main objective of this study is the 
crystallization improvement of ceruloplasmin with these neurotransmitters for further crystallographic 
analysis. The determination of the tri-dimensional structure of these complexes will unveil and con-
firm which protein residues are involved in its binding and stabilization.  
As there is a thigh relationship between protein structure and function it is thought that these 
structural data can help us understand better what is the role of ceruloplasmin in the human brain 
homeostasis and in some neuronal disorders. 
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2. METHODOLOGIES 
2.1. Materials 
In tables 2.1 to 2.3 described all the reagents, solutions, kits, crystallization screens and 
equipments used in the present study. 
 
Table 2.1 | Reagents and manufacturers 
Manufacturers Reagents 
Bio-rad 30% acrylamide/bis solution, Biorad protein assay 
Carl Roth GmbH dipotassium hydrogen phosphate,  glycine, hepes, potassium chloride, sodium 
acetate, sodium citrate tribasic dihydrate, 
Hampton Research Izit crystal dye 
Invitrogen Simply Blue Safe Stain 
Merck Ammonium acetate, ammonium sulfate, bis tris, bromophenol blue, calcium 
chloride, cobalt (II) chloride hexahydrate, copper (II) sulfate pentahydrate, 
ethanol, ethylene glycol, glutaraldehyde, 25% aqueous solution,  imidazole, 
iron (III) chloride hexahydrate, isopropanol, magnesium chloride 
hexahydrate, m-phenylenediamine (MPD), polyethyleneglycol (PEG) 400, 
PEG 4000, PEG 6000, PEG 20000, sodium chloride, sodium formate 
Omnilabor Glycerol, tris-base 
Sigma-Aldrich 2-(cyclohexylamino)ethanesulfonic acid (CHES), 2-(N-morpholino)ethane 
sulfonic acid (MES), 3-(cyclohexylamino)-1-propanesulfonic acid (CAPS), 3-
(N-morpholino) propanesulfonic acid (MOPS), 3,4-Dihydroxy-L-
phenylalanine (L-dopa), cacodylic acid sodium salt, cadmium chloride 
hemi(pentahydrate), dopamine hydrochloride, epinephrine hydrochloride, D 
+ glucose, magnesium acetate tetrahydrate, N,N-Bis(2-hydroxyethyl) gly-
cine, N,N,N′,N′-tetramethyl ethylene diamine (TEMED), PEG 300, PEG 
monomethyl ether 550, PEG1000, PEG3350, PEG 5000, PEG 8000, 
persulfate ammonium (PSA), potassium phosphate monobasic, Serotonin 
hydrochloride powder, sodium iodide, sypro orange protein stain,  tris-(2-
carboxyethyl) phosphine hydrochloride (TCEP) 
 
 
Table 2.2 | Kits, crystallization screens and manufacturers 
Manufacturers Kits and crystallization screens 
Hampton Research Additive screen, Index HT, Natrix HT, SaltRx HT 
Jena Bioscience JBS Solubility Kit 
Molecular Dimensions MIDAS HT-96, Pact Premier HT-96, Structure I+II HT-96, Stura Footprint HT-96 
Quiagen AmSO4 Suite, Nextal MPD Suite, PEGs Suite 
Sigma-Aldrich Gel filtration kit for proteins molecular weights 29-700 kDa 
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Table 2.3 | Equipments, materials and manufacturers 
Manufacturers Equipments and materials 
700 Series Nitrogen Gas Cryosteam Cooler 
Biorad iQ5 Real Time PCR, microseals adhesive seals, multiplate low-profile 96-well 
unskirted PCR plates 
Bruker Corporation X8 Proteum diffractometer AXS system 
Douglas Instruments Oryx-8 crystallization robot 
GE Healthcare AKTA Prime system, superdex 200 10/300 GL gel filtration column (24mL) 
Genomic Solutions Nanorobot Cartesian Microsys 
Hampton Research Cryschem plate (24 well sitting drop plate), VDX plate (24 well hanging drop plate) 
Jena Bioscience MRC 2-well crystallization plate (96 wells) 
Leica MZ16 microscope 
Malvern Instruments Zetasizer Nano Series 
Merck Millipore Amicon Ultra-15 Centrifugal Filter Units MWCO 100 kDa 
Molecular Dimensions Cryoloops and vials  
Rigaku Desktop Minstrel HT UV imaging system 
Thermo scientific NanoDrop 1000 Spectrophotometer 
 
2.2. Methods 
2.2.1. Human ceruloplasmin purification and quantification 
hCp from human sera was previously obtained using the Broman & Kjellin method based on a 
chromatographic purification in presence of inhibitors of proteolysis using a anion exchange column 
followed by a gel filtration column and finally a hydroxyapatite column as described (Moshkov et al., 
1979). Before crystallization a final purification step must be performed to eliminate degradation 
peptides and aggregates. A calibrated superdex 200 10/300 GL gel filtration column was used in a 
AKTA prime system at 277 K. The protein was loaded at a concentration of about 100 mg/mL at a 
flow rate of 0.5 mL/min after equilibration with three column volumes of 0.1 M sodium acetate buffer 
with 0.1 M NaCl, as previously described (Bento et al., 2007). Elution was monitored online at 280 
nm and 1 mL fractions of the relevant peaks were collected and analyzed by native basic poly-
acrylamide gel electrophoresis. The samples were mixed with free SDS and -mercaptoethanol 
loading buffer and immediately loaded in a SDS-free 10% bis-acrylamide gel and analyzed using the 
Simply Blue Safe Stain. The peaks of interest were recovered for concentration using an Amicon 
Ultra-15 MCWO 100 kDa and further protein content determination by the Bradford method 
(Bradford, 1976) using the Bio-rad protein assay reagent and bovine serum albumin as a standard 
and confirmed using a NanoDrop 1000 Spectrophotometer reading UV at 280 nm. 
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2.2.2. Differential scanning fluorimetry (Thermofluor) 
2.2.2.1. Addition of CuSO4, FeCl3 or CoCl2 
 To verify if the presence of CuSO4, FeCl3 or CoCl2 stabilizes hCp and could be helpful in this 
protein crystallization, a thermofluor assay was performed. For each metal a separated assay was 
made in triplicate. Sypro orange protein stain 5000x was used as a fluorescent dye and diluted to 
50x in 25mM hepes pH 7.5 buffer. A mix containing 6.60 L sypro orange protein stain 50x (for 
5x/well), 0.33 L of 25 mg/mL hCp (for a final 2.5 L/well), 0.66 L of 1M CuSO4, FeCl3 or CoCl2 (for 
a final 10 mM/well) and 58.41 L of 0.1 M NaOAc and 0.1 M NaCl buffer, to a final volume of 66 L 
was performed. Another mix was equally performed but with 3.30 L of 1M CuSO4, FeCl3 or CoCl2 
(for a final 50 mM/well). As a control a mix was performed with no metals added and disturbed also 
by 3 wells in the plate. All mixes were distributed by 3 wells (20 L each) in the low-profile 96-well 
unskirted PCR plates and sealed using adhesive microseals. The plate was incubated in the dark for 
5 min and then placed in a iQ5 Real Time PCR. The experiment was run for excitation at 465 nm 
and emission at 590 nm and from 20ºC to 90ºC with 10 seconds cycles 
2.2.2.2. Optimum solubility screening 
2.2.2.2.1. Buffer screen 
To verify if there is any buffer were hCp is more stable than in 0.1 M NaOAc and 0.1 M NaCl, 
a thermofluor using the JBS solubility kit was used. This kit is composed by a set of 24 buffers from 
pH 3 to 10 and in combination with 150 mM NaCl, 150 mM KCl or 500 mM KCl (Table 2.4). Two 
mixes were prepared, the first without CuSO4 and the second with CuSO4. In the first mix, 56.16 L 
of 5.5 mg/mL hCp (for a final 2.5 L/well) were added to190.9 L of 25mM hepes pH 7.5 buffer and 
2.5 L sypro orange 5000x (for a final 5x/well) to a final volume of 249.6 L. This mix was distributed 
by 96 wells in a PCR plate (2 L/well) and 18 L of each buffer from the JBS Solubility kit was added 
to each well in the plate. As a control 0.1 M NaOAc buffer + 0.1 M NaCl was used. In the second 
mix, 2.496 L of 1M CuSO4 (for a final 1 mM/well) were added. The low-profile 96-well unskirted 
PCR plates were sealed, incubated in the dark for 5 min and then placed in an iQ5 Real Time PCR. 
The experiment was run for excitation at 465 nm and emission at 590 nm and from 20ºC to 90ºC 
with 10 seconds cycles. 
2.2.2.2.2. Dynamic light scattering (DLS) 
After analysis of the results and the best buffer conditions in thermal stability assay were 
found, a dynamic light scattering assay was performed to determine which buffer confers more sta-
bility and solubility to hCp (Jancarik et al., 2004). The screening was performed at 20ºC by adding 
500 L of each selected buffer solution into each reservoir. Every buffer was centrifuged to eliminat-
ed any dust, Every drop was prepared at protein:precipitant proportion 1:1 by adding 1 L of reser-
voir solution to 1 L of hCp at 50 mg/mL. All drops were sealed with siliconized glass cover slips and 
the plate was placed at 293 K for 24 hours. During this period, vapor diffusion takes place and, de-
pending on the stability of the protein in a given buffer, clear drops or drops with different degrees of 
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precipitation can be observed under a light microscope. After that time the plate was observed using 
a Leica microscope searching for the drops that are still clear. Those conditions that apparently keep 
the protein in solution were chosen for a DLS assay. The clear drops were then diluted into the 
same reservoir solution at a ratio of 1:2 and a DLS assay was performed using 2 l of sample in a 
Zetasizer Nano Series to determine the homogeneity/monodispersity of the sample. If the protein 
sample appeared to be monodisperse in a particular buffer, then the protein was exchanged into that 
buffer at a final concentration of 100 mM and crystallization screens were performed. 
 
Table 2.4 | Optimum solubility screen buffer (JBS solubility kit). 
No Buffer (0.1 M) pH 
1 Glycine 3 
2 Citric acid 3.2 
3 PIPPS 3.7 
4 Citric acid 4 
5 Sodium acetate 4.5 
6 Sodium/potassium phosphate 5 
7 Sodium citrate 5.5 
8 Sodium/potassium phosphate 6 
9 Bis-tris 6 
10 MES 6.2 
11 ADA 6.5 
12 Bis-tris propane 6.5 
13 Ammonium acetate 7 
14 MOPS 7 
15 Sodium/potassium phosphate 7 
16 HEPES 7.5 
17 Tris 7.5 
18 EPPS 8 
19 Imidazole 8 
20 Bicine 8.5 
21 Tris 8.5 
22 CHES 9 
23 CHES 9.5 
24 CAPS 10 
 
2.2.3. Human ceruloplasmin crystallization  
2.2.3.1. Crystallization screens 
Several crystallization screens were performed trying to obtain a new crystalline form of hCp 
using MRC 2-well crystallization plates (96 wells) and a Nanorobot Cartesian Microsys to perform 
drops of 0.2 L in a protein:precipitant proportion of 1:1 (Table 2.5). The plates were sealed with a 
transparent adherent cover slip and placed at 293 K. The plates were observed after several days 
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and weeks of incubation using a Leica MZ16 microscope including a 10.4 Megapixel digital camera 
for photographs. Although blue protein crystals are expect, due to the type 1 copper centers present 
on hCp,  a Desktop Minstrel HT UV imaging system was used to distinguish salt crystals from pro-
tein crystals since protein fluoresces in the presence of UV because of tyrosine and tryptophan. In 
some cases Izit from Hampton Research was also used to confirm the presence of protein crystals.  
An in house crystallization screen was also performed. The Optiscreen is composed by cres-
cent concentrations of NaCl, PEG3350, AmSO4 or MPD as reservoir solutions. The crystallization 
drop was composed by 0.2 L of a mix solution of hCp at 50 mg/mL and 8% PEG 20 K, 6% PEG 
MME 550, 0.1 M NaOAc, 0.4 M Na formate pH 5.7 and 1 mM CuSO4 at 2:1 proportion. For this case 
in each reservoir was added NaOAc and Na formate pH 5.7 to a final 0.1 and 0.2 M, respectively. 
These reservoir solutions were not added to the drops. 
 
Table 2.5 | Crystallization screens and respective conditions used for hCP crystallization. 
Crystallization  
screen 
hCp concentration 
(mg/mL) 
Protein: precipitant 
drop proportion 
Temperature (K) 
AmSO4 Suite 30 1:1 293 
Index HT 50 1:1 293 
MIDAS HT-96 30 1:1 293 
Natrix HT 30 1:1 293 
Nextal MPD Suite 30 and 40 1:1 277 
Pact Premier HT-96 30 1:1 293 
PEGs Suite 50 and 25 1:1 293 
SaltRx HT 50 1:1 293 
Structure I+II HT-96 40, 50 and 25 1:1 293 
Structure I+II HT-96 30 1:1 277 
Stura Footprint 40, 50 and 25 1:1 293 
 
2.2.3.2. Scale up conditions 
The scaled up drops from hits on crystallization screens were performed using the hanging-
drop or the sitting-drop vapour-diffusion techniques using Cryschem plates (24 well sitting drop 
plate) or VDX plates (24 well hanging drop plate). Usually the protein:precipitant drop proportion is 
made accordingly to the crystallization screen. It can be changed along with the condition modifica-
tion/ improvement. For the crystallization condition construction 500 L of reservoir solution is added 
to the well. For the drop the protein at the desired concentration is first added and then is mixed with 
the reservoir solution at the desired proportion. All drops are sealed using silicone and round glass 
cover slips. All the pates are then placed at desire temperature and observed after days and weeks 
of incubation as described in 2.2.3.1. Some modifications for some conditions were performed in a 
search for better crystals. 
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2.2.3.3. Crystallization assess 
In a first attempt, hCp in 0.1 M NaOAc buffer and 0.1 M NaCl, was also crystallized after puri-
fication as previously described to verify the purity of the protein (Bento et al., 2007). Using the 
hanging-drop vapour-diffusion technique 2 L of protein at 50 mg/mL was mixed with 2 L of a pre-
cipitant solution containing 8% PEG 20K, 8% PEG MME 550, 0.1M sodium acetate, 0.2 M sodium 
formate pH 5.6 in the drop. All drops were sealed with siliconized glass cover slips and placed at 
293 K. Small blue crystals were obtained after about 3 days. In order to improve the aspect and size 
of the crystals several attempts of changing some variants in this condition were made (table 2.6). 
Also CuSO4 was added to the condition in an attempt to stabilize the protein and so the crystals. 
 
Table 2.6 | Crystallization condition improvement (Bento et al., 2007). 
The hanging-drop vapour-diffusion technique was used and the hCp at concentration of 50 mg/mL. 
Protein:precipitant 
drop 
PEG20K 
(%) 
PEG MME 
550 (%) 
NaOAc 
(M) 
Na Formate 
(M) 
CuSO4 
(mM) 
Temperature 
(K) 
2:2 8 8 0.1 0.2 - 293 
1:1 8 8 0.1 0.2 - 293 
2:1 8 8 0.1 0.2 - 293 
2:2 8 8 0.1 0.2 10 293 
2:2 8 8 0.1 0.2 10 293 
2:1 8 8 0.1 0.4 5 293 
2:1 8 8 0.1 0.4 1 293 
2:1 6 12 0.1 0.4 1 293 
2:1 6 16 0.1 0.4 1 293 
2:1 6 20 0.1 0.4 1 293 
2:1 8 12 0.1 0.4 1 293 
2:1 8 16 0.1 0.4 1 293 
2:1 8 20 0.1 0.4 1 293 
2:1 10 12 0.1 0.4 1 293 
2:1 10 16 0.1 0.4 1 293 
2:1 10 20 0.1 0.4 1 293 
2:1 6 16 0.05 0.4 1 293 
2:1 6 16 0.15 0.4 1 293 
2:1 8 16 0.05 0.4 1 293 
2:1 8 16 0.15 0.4 1 293 
2:1 10 16 0.05 0.4 1 293 
2:1 10 16 0.15 0.4 1 293 
2:1 8 12 0.1 0.3 1 293 
2:1 8 16 0.1 0.3 1 293 
2:1 8 20 0.1 0.3 1 293 
2:1 8 16 0.05 0.3 1 293 
2:1 8 16 0.1 0.3 1 293 
2:1 8 16 0.15 0.3 1 293 
2:1 8 8 0.1 0.5 1 293 
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Table 2.6 | Crystallization condition improvement (Bento et al., 2007) (Continued).   
The hanging-drop vapour-diffusion technique was used and the hCp at concentration of 50 mg/mL 
Protein:precipitant 
drop 
PEG20K 
(%) 
PEG MME 
550 (%) 
NaOAc 
(M) 
Na Formate 
(M) 
CuSO4 
(mM) 
Temperature 
(K) 
2:1 8 8 0.1 0.4 1 277 
2:1 8 8 0.1 0.5 1 277 
2:1 8 12 0.15 0.4 1 293 
2:1 8 20 0.15 0.4 1 293 
2:1 6 16 0.1 0.3 1 293 
2:1 6 16 0.1 0.5 1 293 
2:1 10 16 0.1 0.3 1 293 
2:1 10 16 0.1 0.5 1 293 
2:1 8 16 0.1 0.5 1 293 
2:1 8 16 0.15 0.5 1 293 
2:1 6 12 0.1 0.3 1 293 
2:1 6 6 0.1 0.3 1 293 
2:1 4 6 0.1 0.3 1 293 
2:1 6 6 0.1 0.4 1 303 
2:1 6 12 0.1 0.4 1 303 
2:1 6 16 0.1 0.4 1 303 
2:1 8 8 0.1 0.4 1 303 
2:1 8 12 0.1 0.4 1 303 
2:1 8 12 0.15 0.4 1 303 
2:1 6 6 0.1 0.4 1 277 
2:1 6 12 0.1 0.4 1 277 
2:1 6 16 0.1 0.4 1 277 
2:1 8 8 0.1 0.4 1 277 
2:1 8 12 0.1 0.4 1 277 
2:1 8 12 0.15 0.4 1 277 
2:1 8 8 0.15 0.4 1 303 
2:1 8 6 0.1 0.4 1 303 
2:1 8 8 0.15 0.4 1 303 
2:1 8 8 0.1 0.3 1 303 
2:1 8 16 0.1 0.5 1 303 
2:1 8 16 0.1 0.4 1 303 
2:1 8 16 0.15 0.5 1 303 
2:1 8 14 0.1 0.4 1 293 
2:1 8 8 0.1 0.3 1 293 
2:1 4 4 0.1 0.4 1 277 
2:1 4 6 0.1 0.4 1 277 
2:1 4 8 0.1 0.4 1 277 
2:1 6 4 0.1 0.4 1 277 
2:1 6 8 0.1 0.4 1 277 
2:1 6 4 0.1 0.4 1 293 
Chapter 2: Methodologies 
“Human ceruloplasmin and neurotransmitters: complex stabilization and crystallization” 
   34 
Table 2.6 | Crystallization condition improvement (Bento et al., 2007) (Continued).   
The hanging-drop vapour-diffusion technique was used and the hCp at concentration of 50 mg/mL. 
Protein:precipitant 
drop 
PEG20K 
(%) 
PEG MME 
550 (%) 
NaOAc 
(M) 
Na Formate 
pH 5.7 (M) 
CuSO4 
(mM) 
Temperature 
(K) 
2:1 6 8 0.1 0.4 1 293 
2:2 8 6 0.1 0.4 1 293 
2:0.5 8 6 0.1 0.5 1 293 
2:1 6 10 0.1 0.4 1 293 
2:1 6 14 0.1 0.4 1 293 
2:1 8 10 0.1 0.4 1 293 
2:1 8 14 0.1 0.4 1 293 
2:1 10 6 0.1 0.4 1 293 
2:1 10 8 0.1 0.4 1 293 
2:1 10 10 0.1 0.4 1 293 
2:1 10 14 0.1 0.4 1 293 
2:1 8 10 0.1 0.5 1 293 
2:1 8 12 0.1 0.5 1 293 
2:1 8 14 0.1 0.5 1 293 
2:1 8 16 0.1 0.5 1 293 
 
A condition previously described (Zaitseva et al., 1996) was also investigated and several 
modifications were performed in a search for bigger and better crystals (table 2.7).   
Another hCp structure available in the PDB (http://www.rcsb.org/pdb/home/home.do) with the code 
4ENZ was achieved using crystal grown in a precipitant solution 40% MPD, 0.1 M NaCl, 0.1 M NaOAc 
pH 4.6 and 0.01 M CaCl2 at 280 K using the sitting drop vapor diffusion method. This condition was 
reproduced and some alterations were made in an attempt to have better crystals (table 2.8). 
 
Table 2.7 | Crystallization condition modification and improvement (Zaitseva et al., 1996). 
The hanging-drop vapour-diffusion technique was used and the hCp at concentration of 50 mg/mL. 
Protein:precipitant  PEG20K (%) NaOAc pH 5.5 (M) NaCl (M) CuSO4 (mM) Temperature (K) 
0.5:0.5 3 0.1 0.1 - 293 
0.5:0.5 3 0.1 0.25 - 293 
0.5:0.5 3 0.1 0.4 - 293 
0.5:0.5 5 0.1 0.1 - 293 
0.5:0.5 5 0.1 0.25 - 293 
0.5:0.5 5 0.1 0.4 - 293 
0.5:0.5 7 0.1 0.4 - 293 
0.5:0.5 7 0.1 0.4 - 293 
0.5:0.5 7 0.1 0.4 - 293 
0.5:0.5 10 0.1 0.4 - 293 
0.5:0.5 10 0.1 0.5 1 293 
0.5:0.5 10 0.1 0.4 1 293 
0.5:0.5 10 0.15 0.4 1 293 
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Table 2.7 | Crystallization condition modification and improvement (Zaitseva et al., 1996) (Continued).   
The hanging-drop vapour-diffusion technique was used and the hCp at concentration of 50 mg/mL. 
Protein:precipitant  PEG20K (%) NaOAc pH 5.5 (M) NaCl (M) CuSO4 (mM) Temperature (K) 
0.5:0.5 10 0.2 0.4 1 293 
0.5:0.5 12 0.1 0.5 1 293 
0.5:0.5 12 0.1 0.4 1 293 
0.5:0.5 12 0.1 0.5 1 293 
0.5:0.5 12 0.1 0.4 1 293 
0.5:0.5 12 0.15 0.4 1 293 
0.5:0.5 12 0.2 0.4 1 293 
0.5:0.5 15 0.1 0.5 1 293 
0.5:0.5 15 0.1 0.4 1 293 
0.5:0.5 15 0.15 0.4 1 293 
0.5:0.5 15 0.2 0.4 1 293 
1:0.5 3 0.1 0.3 1 277 
1:0.5 5 0.1 0.3 1 277 
1:0.5 8 0.1 0.3 1 277 
1:0.5 10 0.1 0.5 1 293 
1:0.5 10 0.1 0.4 1 293 
1:0.5 10 0.15 0.4 1 293 
1:05 10 0.2 0.4 1 293 
 
Table 2.8 | Crystallization condition modification and improvement. 
The hanging-drop vapour-diffusion technique was used and the hCp at concentration of 50 mg/mL. 
Protein:precipitant  MPD (%) NaOAc pH 5.5 (M) NaCl (M) CaCl2 (mM) Temperature (K) 
0.5:0.5 30 0.1 0.05 0.01 277 
0.5:0.5 30 0.1 0.1 0.01 277 
0.5:0.5 30 0.1 0.15 0.01 277 
0.5:0.5 30 0.05 0.1 0.01 277 
0.5:0.5 30 0.15 0.1 0.01 277 
0.5:0.5 30 0.2 0.1 0.01 277 
0.5:0.5 35 0.1 0.05 0.01 277 
0.5:0.5 35 0.1 0.1 0.01 277 
0.5:0.5 35 0.1 0.15 0.01 277 
0.5:0.5 35 0.05 0.1 0.01 277 
0.5:0.5 35 0.15 0.1 0.01 277 
0.5:0.5 35 0.2 0.1 0.01 277 
0.5:0.5 40 0.1 0.05 0.01 277 
0.5:0.5 40 0.1 0.1 0.01 277 
0.5:0.5 40 0.1 0.15 0.01 277 
0.5:0.5 40 0.05 0.1 0.01 277 
0.5:0.5 40 0.15 0.1 0.01 277 
0.5:0.5 40 0.2 0.1 0.01 277 
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2.2.3.4. Additive screen 
The hanging-drop vapour-diffusion method was applied to the additive screen (see 7.Anex, 
table 7.1). The drop was made using as precipitant a previous optimized condition and pro-
tein:precipitant:additive drop proportion was of 1:0.4:0.1 for a final drop of 1.5 L and 500 L of res-
ervoir solution. All the different 96 additives were tested. The plates were treated and all the drops 
observed as described in 2.2.3.1. Those conditions which gave rise to good crystals were confirmed 
as being protein crystals and repeated. 
2.2.3.5. Seed Screen 
Crystals obtained using the previous optimized conditions were placed in 50 L of their re-
spective reservoir solution and mechanically homogenized on a standard laboratory vortex for 2 min 
at full speed for microseeds. Vapour-diffusion crystallization experiments and automated seeding 
were performed using an Oryx-8 crystallization robot. A ‘matrix-seeding script’ for the Oryx-8 robot 
allowed the simultaneous dispensing of protein, reservoir solutions and seeding stocks (D'Arcy et al., 
2007). In control experiments (no seeds added), 0.3 ml screening solution was added to 0.3 ml pro-
tein solution in 96-well MRC 2-well crystallization plate; the reservoir wells contained 50 L of the 
screen solution (structure I+II). For screens with seeding, 0.2 L screening solution and 0.1 L 
microseeds were added to 0.3 Ll protein solution using the same system as described above. The 
plates were sealed with clear plastic tape and incubated at 293 K. All drops were observed after a 
few days to several weeks and crystals confirmed as being protein crystals as described in 2.2.3.2.  
2.2.3.6. Crosslinking experiments 
To crosslink hCp crystals for a chance at improved handling using hanging drops the cover 
slip was transferred to a sitting drop plate with 4 L of 25% glutaraldehyde into the sitting drop sit 
and 500 L of crystallization solution into the surrounding reservoir. The drop was sealed with sili-
cone and incubated from 30 min to 2 hours, allowing the glutaraldehyde to vapor diffuse into the 
sample drop containing the crystals. Crystals were then transferred for stabilizing/cryo solution drops. 
2.2.3.7. Co-crystallizations 
2.2.3.7.1. hCp with CuSO4, FeCl2 and CoCl2 
Ceruloplasmin was incubated with metals for posterior co-crystallization. Incubation of hCp at 
55 mg/mL with 10 mM of CuSO4, FeCl3 or CoCl2 were made and placed at 277 K for 20 hours. This 
incubation was used to construct hanging-drop vapour-diffusion plates using a selected reservoir 
condition of 500 L in the reservoir and a protein:precipitant proportion of 2:1 in the drop for a final 
volume of 3 L. The plates were incubated at 293 K and observed as described in 2.2.3.1.                                                                                
2.2.3.7.2. hCp with serotonin, epinephrine, dopamine and L-dopa 
Several incubations were made regarding different concentrations of hCp and neurotransmit-
ters (table 2.9). Some crystallization screens at 1:1 protein:precipitant drop proportion (table 2.10) 
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and scaled up drops were performed as previously described in a search for co-crystals. Some co-
crystallization drops were performed using the incubations performed and a previous established 
reservoir solution / precipitant with some modifications (Bento et al., 2007). Then the crystals were 
transferred to equilibrated cryoprotectant drops before being freeze to 100 K in liquid nitrogen for 
further analysis by X-ray diffraction.   
 
Table 2.9 | Ceruloplasmin and neurotransmitters incubations. 
All incubations were performed at 277 K for about 24 hours. 
Neurotransmitter [Neurotr.] (mM) [hCp] (mg/mL) 
Dopamine 10 50 
 10 25 
 5 25 
 2 25 
 1 50 
Epinephrine 10 50 
 10 25 
 5 25 
 2 25 
 1 50 
L-Dopa 0.5 50 
Serotonin 1 50 
 
2.2.3.8. Soaking experiments 
For hCp crystals soaking with neurotransmitters assay, the previously selected cryoprotectant 
condition was made and using the sitting-drop vapour-diffusion technique 500 L of reservoir solu-
tion was used in the well and 5 L in the drop. The drops were sealed and incubated for 30 min at 
desired temperature. Blue hCp crystals previously grown at optimum conditions were transferred to 
the cryoprotectant drops and then were soaked with the neurotransmitters at different concentration 
and incubated for several hours (table 2.10) before being freeze to 100 K in liquid nitrogen for further 
analysis by X-ray diffraction.   
Table 2.10 | Crystallization screens for hCp and neurotransmitters co-crystallization. 
All screens were incubated at 293 K. 
Neurotransmitter [Neurotr.] (mM) [hCp] (mg/mL) Crystal. screen 
Dopamine 10 50 Structure I&II 
Stura footprint 
 5 25 Stura footprint 
 2 25 Optiscreen 
Epinephrine 10 50 Structure I&II 
Stura footprint 
 5 25 Stura footprint 
 2 25 Optiscreen 
Chapter 2: Methodologies 
“Human ceruloplasmin and neurotransmitters: complex stabilization and crystallization” 
   38 
Table 2.11 | hCp soaking experiments with neurotransmitters. 
All incubations were made at 293 K. 
Neurotransmitter Neurotransmitter 
(mM) 
Soaking time  
(hours) 
Dopamine 1 20 
 3 20 
 5 3 
 5 20 
 10 20 
Epinephrine 1 5 
 1 20 
 3 20 
 5 3 
 5 20 
 10 20 
L-dopa 2 20 
 5 3 
 5 20 
Serotonin 2 20 
 5 20 
 5 3 
 
2.2.4. Crystals cryoprotection 
Prior to freeze crystals for X-ray analysis it is necessary to protect them against the cold tem-
peratures. To do so crystals need to be transferred to an optimum cryoprotectant solution capable of 
preserve the crystals in their form and diffraction. Several cryoprotectants were added to the crystal-
lization condition in order to found the best one in preserving the crystals: 25% PEG MME 550, 25% 
ethyleneglycol, 20% glycose, 25% MPD. The drops were set using the sitting-drop vapour-diffusion 
method in 24 well plates. The reservoir solution was added to the reservoir (500 l) and to the drop 
(5 L). Drops and plates were closed and incubated for 30 min at the desired temperature (277 or 
293 K). Then the crystals were transferred to the equilibrated cryoprotectant drops and were ob-
served for several hours to check if they preserve their form of if they start dissolving. The crystals 
were then fished from the solution using different sizes cryoloops and placed on vials to be freeze to 
100 K in liquid nitrogen for further analysis by X-ray diffraction.   
2.2.5. Crystals X-ray analysis 
Crystals were analyzed in the in house X8 Proteum diffractometer AXS system at Macromo-
lecular Crystallography Unit at ITQB or at the European Synchrotron Radiation Facility at Grenoble, 
France, at beamline ID14-1, a fixed energy station dedicated to high-throughput macromolecular 
crystallography (ADSC Q210 CCD and XFlash fluorescence detectors), and ID23-1 (ADSC Q315R 
detector). 
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3. RESULTS 
This work started with a final purification step to eliminate hCp aggregates or degradation, as 
the purified protein samples were kept frozen at - 80 ºC for quite some time. The strategy of this work 
is described in figure 3.1. After the purification and the determination of the protein concentration a 
differential scanning fluorimetry assay was performed to the protein in its present buffer (0.1 M NaOAc 
pH 8.8 and 0.1 M NaCl). This technique can determine if a given protein is stable in a given buffer 
which is required for crystallization or if a given ligand is capable of stabilized a given protein under 
determined conditions. After performing the thermofluor assay the best ligand was found to stabilize 
hCp. Then a solubility screen was also used for thermofluor analysis in order to find a buffer capable 
of preventing the protein aggregation which can inhibit crystal nucleation or growth. After find the best 
buffer, hCp was ready for crystallization alone or in combination with neurotransmitters. 
3.1. Ceruloplasmin purification 
To eliminate the aggregates and degradation present in the previously purified hCp samples a 
final size exclusion purification step was performed using a superdex 200 10/300 GL of 24 mL column. 
The sample was loaded in the column using 0.1 M NaOAc and 0.1 M NaCl as buffer and run at a flux 
of 0.5 mL/min for about 50 min. The run was followed by UV detection at 280 nm and the resulting 
chromatogram is shown in Figure 3.2, a). A first peak is seen about 16 min after sample injection. This 
corresponds to 8 mL which is the void volume of this column and corresponds to high molecular 
weight proteins coming first out of the column. Around 24 min after the injection another peak is ob-
served. This peak corresponds to the 132 kDa hCp coming out of the column after 12 mL column vol-
ume with some smaller molecular weight peptides. These smaller peptides are hCp subunits. hCp is 
known to originate polypeptides of 67 kDa, 50 kDa and 19 kDa spontaneously when is not fully stable 
(Kingston et al., 1977). hCp has an isoelectric point of 5.5 and is easily degraded in several subunits 
when in the presence of SDS or -mercaptoehanol as this protein has 5 disulphide bridges connecting 
the 6 domains. Thus, a native basic polyacrylamide electrophoresis gel on samples from size exclu-
sion purification was performed to avoid protein degradation. As observed in figure 3.2, b) there is a 
higher molecular weight protein corresponding to the full hCp and some small peptides. The gel filtra-
tion fractions 4, 6, 8, 9, 10, 11, 12 and 13 were analyzed on gel jointly with hCp sample before size 
exclusion purification. At “hCp” lane in figure 3.12 b) high molecular weight aggregates are observed 
along with the hCp and also some degraded subunits. In lanes “4” and “6” only the high molecular 
weight aggregates are present. Purification sample fractions 8 to 12 were pooled together and con-
centrated up to 50 mg/mL. Protein concentration was performed using Amicon Ultra-15 Centrifugal 
Filter Units MWCO 100 kDa. The cut-off of 100 kDa was chosen in an attempt to eliminate the ~60 
kDa degraded peptides present in the samples, in order to have a more pure hCp final sample. Protein 
concentration was determined by Bradford method and confirmed by UV using a NanoDrop 1000 
Spectrophotometer. In figure 3.2, c) is the native basic gel analysis of the final hCp sample. As ob-
served the smaller peptides were not completly eliminated. To confirm if the final sample is stable and 
ready to crystallize a DSF followed by a solubility screen were performed prior to crystallization asses. 
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Figure 3.1 | Work strategy diagram. 
hCp + neurotransmitters crystallization assays: 
o Co-crystals: 
 Crystallization screens 
 Scaled up drops: 
 Hanging-drop vapour-diffusion 
 Sitting-drop vapour-diffusion 
 
o Soaking crystals 
 
hCp crystallization assays: 
o Crystallization screens 
o Scaled up drops: 
 Hanging-drop vapour-diffusion 
 Sitting-drop vapour-diffusion 
 
o Additive screen 
hCP crystallization in: 
o 0.1 M NaAc pH 8.8 + 0.1 M NaCl  
o 0.1 M bicine pH 8.5 + 0.15 M NaCl 
Size exclusion purification described by 
 (Bento et al., 2007) 
hCp in 0.1 M NaAc pH 8.8 + 0.1 M NaCl 
Differential scanning fluorometry  
hCp in 0.1 M NaAc pH 8.8 + 0.1 M NaCl 
o FeCl3 
o CuSO4 
o CuCl2 
Differential scanning fluorometry  
hCp buffer screen with/without CuSO4 
Dynamic light scattering 
hCp buffer screen selected solutions 
hCp selected buffer exchange 
0.1 M bicine pH 8.5 + 0.15 M NaCl 
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Figure 3.2 | Ceruloplasmin final size exclusion purification step. a) Resultant chromatogram at 280 nm. 
b) Native basic PAGE of the purification samples: M, marker; hCp, ceruloplasmin prior purification at 
~100mg/mL with high molecular weight aggregates; 4-13; corresponding collected samples in the chroma-
togram in a). c) Final native basic gel after concentration of pure hCp up to 50 mg/mL using a 100kDa cut 
off filter, some smaller subunits are still present at a minor concentration.   
 
3.2. Ceruloplasmin stability and solubility evaluation 
Purified ceruloplasmin is stable in 0.1 M NaOAc pH 8.8 with 0.1 M NaCl as previously de-
scribed (Bento et al., 2007).  However, conditions that stabilize proteins can improve protein purifica-
tion and crystallization. Protein thermal stability was analyzed and evaluated by differential scanning 
fluorimetry and dynamic light scattering. The first technique can determine if a given protein is stable 
in a given buffer which is required for crystallization. The tendency of proteins to aggregate decreas-
es under stabilizing conditions. Also some ligands can help stabilizing a protein by the protein-ligand 
interaction. The stability of most proteins decreases with the increase of the temperature. When the 
concentrations of folded and unfolded protein are equal the temperature is considered as melting 
temperature (Tm). When a compound binds to a protein, the protein-ligand complex is usually more 
stable and in most cases results in an increase in the Tm (Niesen et al., 2007).  
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3.2.1. Differential Scanning Fluorimetry 
Protein stabilization by ligands may significantly improve the quality of purified proteins and 
also aid the crystallization process. The more favorable conditions will lead to a higher Tm. As hCp 
is a copper protein capable of oxidizing iron, both CuSO4 and FeCl2 were investigated about their 
capacity to stabilize hCp (figure 3.3). An assay using CoCl2 was also performed as cobalt has been 
described as being capable of binding to copper centers (Lindley et al., 1997). Also different buffers 
were analyzed as potential better stabilizers for hCp crystallization than the present buffer used for 
its purification. 
The fluorescent Sypro Orange was used in the thermofluor assays. When a protein starts to 
unfold this dye binds to the exposed hydrophobic parts of the protein resulting in an increase in the 
fluoresce emission along with the unfolding. The fluorescence intensity reaches a maximum as then 
decreases doe to precipitation and denatured protein. Plots of fluorescence intensity versus temper-
ature were obtained showing a sigmoid shape expected for a two-state unfolding mechanism, and 
the temperature at which 50% of the protein is unfolded (Tm) can be estimated from the inflexion 
point of the curves (figure 3.3 and table 3.1). The melting curve for hCp alone showed two transition 
curves which indicate that this protein does not unfold globally. This biphasic melt curves shows a 
first peak with a Tm of 54ºC and a second higher peak of Tm 74ºC.This might indicate that the pro-
tein dissociates, which is expected since it is know that it originate polypeptides of 67 kDa, 50 kDa 
and 19 kDa spontaneously when is not perfectly stable. But when in the presence of CuSO4 only 
one shift is observed and although the Tm is of 66ºC it seems that copper is capable of stabilizes 
this protein in a global way. Iron (III) seems not to cause any change in protein stabilization. The 
presence of cobalt seems to cause some destabilization and the protein dissociation is faster and 
higher. A higher concentration of Co originates a one phase curve with a lower Tm (47ºC). In all the 
cases a lower concentration of metal (10 mM) is better for the protein originating a higher Tm. High 
concentrations of metal might cause protein-metal precipitation. These results show that CuSO4 
seems to stabilize hCp and it could be useful for crystallization. However, as metal solutions and 
hCp samples are colorful this might also interfere with the results. 
One application of the buffer screen is to find a suitable buffer for a particular protein, espe-
cially if the protein aggregates or precipitates from solution in the buffer of choice given that this 
might be correlated with protein stability. The buffer screen consisted of a set of 24 different buffers 
at a concentration of 0.1 M and with a pH from 3 to 10 alone or in combination with NaCl or KCl. 
This set of buffers were tested by differential scanning fluorimetry in order to obtain the most homo-
geneous and monodisperse protein conditions for hCp which tendency is to aggregate. Two different 
assays were performed, one with no CuSO4 and the other adding 10 mM of CuSO4 (figures 3.4 and 
3.5). For some reason precipitation was observed when adding 10 mM CuSO4 to the protein and 
Sypro Orange mix. This was not verified in the previous assay. Nevertheless, 1 mM CuSO4 was 
then added to the mix and no precipitation was observed.  
The hCp Tm values measured for each buffer were compared with the Tm values for the con-
trol experiments. A higher Tm can be coupled to an increase in structural order and a reduced con-
formational flexibility, whereas a decrease in stability, lower Tm, indicates that the buffer induces  
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Table 3.1 | Metal-dependent hCp stabilization and melting temperatures. 
DSF assay 1st peak Tm (ºC) 2nd peak Tm (ºC) 
hCp 54 74 
hCp + 10 mM CuSO4 69 - 
hCp + 50 mM CuSO4 58 - 
hCp + 10 mM CoCl2 52 79 
hCp + 50 mM CoCl2 47 - 
hCp + 10 mM FeCl3 54 74 
hCp + 50 mM FeCl3 53 73 
 
protein structural changes toward a more disordered conformation or it can be a sign of misfolding. 
However, not only the Tm value is important, the shape of the melting curve is also a parameter to 
consider. A one transition melting curve is desirable as it indicates the global folding of the protein 
and a higher stability. In figure 3.4 the Tm for all buffers thermofluor assay are represented. As con-
trol ceruloplasmin in 0.1 M NaAc pH 8.8 plus 0.1 M NaCl was used and the biphasic melting curve 
exhibiting two Tm’s (54/74ºC). In graphic A) no salt was added to any buffer and as observed for 
almost every buffer two Tm transitions are observed except for EPPS pH 8.0 (Tm = 57ºC), imidazole 
pH 8.5 (Tm = 52ºC), bicine pH 8.5 (Tm = 53ºC), tris pH 8.5 (Tm = 58ºC), CHES pH 9.0 (55ºC) and 
CAPS pH 10.0 (Tm = 55ºC). All this six buffers were chosen for a solubility test by hanging-drop 
vapour-difusion method. In figure 3.4, B) all hCp Tm for buffers in combination with 150 mM NaCl 
are shown. Only one buffer exhibited a one transition melting curve, 0.1M bicine pH 8.5 (Tm = 
57ºC). This condition was also analyzed by the solubility test. In graphics C) and D) all buffers, in 
combination with 150 mM KCl and 500 mM KCl, respectively, showed to originate a hCp biphasic 
melting curve and therefore were not chosen for solubility test or dynamic light scattering. It seems 
that salts destabilize this protein. 
As CuSO4 was identified as being capable of stabilize ceruloplasmin in 0.1 M NaAc pH 8.8 
plus 0.1 M NaCl, it was added to the buffer screen in an attempt to stabilize the protein and one 
transition melting curve was expected for more conditions than the ones obtained for the screen 
without copper. In figure 3.5 the melting temperatures for hCp in the presence of buffers in combina-
tion with 1 mM CuSO4 are shown. As observed several conditions in presence of CuSO4 are capa-
ble of stabilizing better ceruloplasmin, which exhibits one melting curve. The Tm values for those 
cases are between the two Tm points observed for the respective buffers in the absence of CuSO4. 
This is observed for both cases with and without salt. However, there are several conditions that 
cause protein precipitation and no valid melting curves are exhibited. For higher pH with no salt this 
is observed, meaning that hCp at higher pH in the presence of CuSO4 causes protein destabilization 
and consequent denaturation and precipitation (Figure 3.5, A). Ceruloplasmin seems also to be un-
stable at pH 7.0 – 8.0 in the presence of CuSO4. The conditions, at 100mM in combination with 1 
mM CuSO4, NaAc pH 4.5 (Tm = 58/70ºC), ammonium acetate pH 7.0 (Tm = 56ºC), MOPS pH 7.0 
(Tm = 57ºC), imidazole pH 8.0 plus 0.15 M NaCl (Tm = 60ºC), tris pH 8.5 plus 0.15M NaCl (Tm = 
64ºC), MES pH 6.2 plus 0.15 M KCl (Tm = 63ºC), bicine pH 8.5 plus 0.15 M KCl (Tm = 66ºC) were 
chosen for a solubility test by hanging-drop vapour-difusion method. 
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Figure 3.3 | Normalized graphics of ligand-dependent hCp stabilization measured by differential 
scanning fluorimetry. Metals CuSO4, FeCl3 or CoCl2 were added to each assay at a final concentration of 
10 mM or 50 mM. All the assays were performed in 0.1 M NaOAc pH 8.8 buffer with 0.1 M NaCl. The control 
assay was performed with hCp alone at same conditions.  
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Figure 3.4 | Melting temperatures for hCp in the presence of buffers listed in table 2.4. All buffers are 
at 0.1 M. hCp purification buffer 0.1 M NaAc pH 8.8 with 0.1 M NaCl was used as control buffer. Salts were 
added to the assay: A) No salt; B) 150 mM NaCl; C) 150 mM KCl; D) 500 mM KCl.  
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Figure 3.5 | Melting temperatures for hCp in the presence of buffers listed in table 2.4 and 1 mM 
CuSO4. All buffers are at 0.1 M. As control hCp purification buffer 0.1 M NaAc pH 8.8 with 0.1 M NaCl was 
used. Salts were added to the assay: A) No salt; B) 150 mM NaCl; C) 150 mM KCl; D) 500 mM KCl.  
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In all cases, hCp at low pH between 3-3.5 always precipitate, it is known that at acidic pH 
copper centers disrupt and copper dissociates from the protein, causing in this case the denaturation 
and precipitation of hCp. As explained before not only the melting temperature values are important 
but also the shape of the curve. In figure 3.6 are shown the curves for selected buffers with (B) and 
without CuSO4 (A). As control was used the hCp purification buffer 0.1 M NaAc pH 8.8 with 0.1 M 
NaCl with or without CuSO4. A one transition midpoint curve is preferable to that biphasic but also a 
sharper curve is desirable. Sharper curves are observed in the presence of CuSO4. However, in the 
presence of copper there are some precipitation maybe between the copper and the Sypro Orange 
dye and a medium high fluorescence is observed at the starting temperature of the assay (25ºC).  
The best thermal shift curves for hCp buffer screen were tested using the hanging-drop vapor-
diffusion method to monitor precipitation. All the conditions leaded to clear drops are were selected 
for DLS characterization to determine the best condition.  
 
 A) 
 
 
 
 
 
 
 
 
 
 
 
 B) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 | Normalized graphics of best buffers for hCp stabilization measured by differential scan-
ning fluorimetry. A) assay performed with no CuSO4; B) assay performed with 1 mM CuSO4. All buffers 
are at 0.1 M. As control hCp purification buffer 0.1 M NaAc pH 8.8 with 0.1 M NaCl was used.  
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3.2.2. Dynamic light scattering (DLS) 
The DLS technique measures Brownian motion (random moving of particles suspended in 
a fluid (a liquid or a gas) resulting from their collision by the fast-moving atoms or molecules in the 
gas or liquid) and relates it to the size of the particles. It does this by illuminating the particles with a 
laser and analyzing the intensity fluctuations in the scattered light. The main purpose of using DLS in 
crystal screening is to help to understand the size distribution, stability, and aggregation state of 
proteins in solution. 
Ceruloplasmin solubility in the buffer solutions listed in the table 3.2 was analyzed through 
DLS. The results show the radius in nm (for globular proteins) calculated by the DLS analysis. When 
the diameter and radius can be calculated the molecular weight can be inferred. In table 3.2 are 
describe the results for the DLS analysis. A molecular weight greater than the expected for hCP of 
about 132 kDa indicates aggregation and a lower one points to degradation of the protein. When a 
particle is alone and equal in a given solution only a peak should be detected and the intensity of the 
fluctuation should be 100%. When particles of different sizes are present in a solution more than one 
peak of intensity will be detected. In this experiment some results could not be obtained for some 
solutions maybe because of the presence of aggregates. For several buffers the indication of pres-
ence of a particle or protein with 145 kDa has been determined. This molecular size is very close to 
the one of hCp. However, only one buffer, 0.1M bicine pH 8.5 + 0.15M NaCl, showed 100% in one 
peak intensity and given this properties this buffer was chosen for hCp stabilization. 
 The hCp was in part exchanged for this buffer by dialysis at 40 mg/mL and the other part was 
kept in 0.1 M NaAc pH 8.8 + 0.1 M NaCl both for further crystallization. 
 
Table 3.2 | Dymanic light scattering results for hCp-buffer assays at 20ºC. 
Buffer (0.1M) R.nm MW.kDa Int.% 
EPPS pH 8 6.0 220 79 
Bicine pH 8.5 5.0 145 83 
Tris pH 8.5 5.0 145 81 
CHES pH 9 3.75 75 91 
CAPS pH 10 4.35 105 75 
Bicine pH 8.5 + 0.15M NaCl 5.0 145 100 
NaAc pH 8 + 1mM CuSO4 6.5 250 89 
AmAc pH 7 + 1mM CuSO4 n/d n/d - 
MOPS pH 7 + 1mM CuSO4 n/d n/d - 
Imidazole pH 8 + 0.15M NaCl + 1mM CuSO4 5.0 145 94 
Tris pH 8.5 + 0.15M NaCl + 1mM CuSO4 3.75 75 88 
MES pH 6.2 + 0.15M KCl + 1mM CuSO4 n/d n/d - 
Bicine pH 8.5 + 0.15M KCl + 1mM CuSO4 5.0 145 82 
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3.3. Human ceruloplasmin crystallization 
Ceruloplasmin crystals that have been previously obtained have a high solvent content of 
about 70% (Bento et al., 2007; Zaitseva et al., 1996). This makes them poor diffracting crystals be-
ing difficult to solve the complete tridimensional structure of this protein. In order to improve these 
crystals or find a new crystal form that allows a reduction in the unit cell and so a different packing, 
several techniques of crystallization where performed. 
3.3.1. Crystallization conditions improvement 
After the dialysis of hCp in 0.1 M NaAc pH 8.8 and 0.1 M NaCl to 0.1 M bicine pH 8.5 and 
0.15 M NaCl crystallization conditions were performed for hCp in both buffers As a first attempt of 
getting some hCp crystals some 4 L drops were prepared as described in (Bento et al., 2007). hCp 
at 50 mg/mL in 0.1 M NaAc and 0.1 M NaCl was mixed in the drop in a ratio 2:2 with 8% PEG 20K, 
8% PEG MME 550, 0.1 M NaAc and 0.2 M Na formate pH 5.7 as precipitant solution. The hanging-
drop vapour-diffusion technique at 293 K gave rise to the 0.05x0.05x0.01 nm blue hexagonal crys-
tals shown is figure 3.7, a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 | hCp blue crystals using the hanging-drop vapour diffusion method at 293 K. a) 8% PEG 
20K, 8% PEG MME 550, 0.1 M NaAc and 0.2 M Na formate pH 5.7; b) 8% PEG 20K, 8% PEG MME 550, 0.1 
M NaAc, 0.2 M Na formate pH 5.7 and 1 mM CuSO4; c) 6% PEG 20K, 12% PEG MME 550, 0.1 M NaAc, 0.4 
M Na formate pH 5.7 and 1 mM CuSO4; d) 6% PEG 20K,16% PEG MME 550, 0.1 M NaAc, 0.4 M Na formate 
pH 5.7 and 1 mM CuSO4; e) 8% PEG 20K, 12% PEG MME 550, 0.1 M NaAc, 0.4 M Na formate pH 5.7 and 1 
mM CuSO4; f) 8% PEG 20K, 12% PEG MME 550, 0.15 M NaAc, 0.4 M Na formate pH 5.7 and 1 mM CuSO4. 
a)                                                   b) 
 
 
 
 
 
 
 
 
 
 
 
c)                                                               d) 
 
 
 
 
 
 
 
 
 
 
 
e)                                                               f)   
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In an attempt to get bigger and better crystals 1, 5 and 10 mM CuSO4 were added to the precipitant 
solution in the crystallization drops. In drops with 1 mM CuSO4 blue crystals have grown in a few 
days (figure 3.7, b). These crystals are also small but thicker than the ones grown without CuSO4. 
Several modifications were made to this condition in a search for bigger and better diffracting crys-
tals: changing the drop proportion or the concentration of the compounds in the precipitant solution. 
The hexagonal crystals have sizes between 0.5 and 1.5 nm of diameter. However, these crystals 
are not always reproducible in these conditions, so some modifications were still made in search for 
reproducibility. After several attempts described in table 2.6 were made, a condition with more re-
producibility was found: 8% PEG 20K, 6% PEG MME 550, 0.1 M NaAc, 0.4 M Na formate pH 5.7 
and 1 mM CuSO4 using the hanging drop method with a protein:precipitant proportion of 2:1. Blue 
thick crystals were obtained with 0.15 to 0.20 nm of diameter and are thicker than the ones ob-
served before (figure 3.8). This condition were adapted and some drops were also performed at 277 
K in an attempt to slower the evaporation in the drop creating a slower equilibration on the drop in 
order to allow the nucleation to occur and then the slow crystal growth and get bigger crystals. How-
ever, this low temperature and slow evaporation could originate more nucleation, originating more 
crystals and smaller, instead of less and bigger crystals. As observed in figure 3.9, that was what 
happened on this case, there were more, smaller and thinner crystals in the drop. The same drops 
were repeated and placed at 303 K trying to speed the evaporation and diminish the nucleation but 
no crystals have grown in the drops, maybe due to protein denaturation. hCp is more stable at lower 
temperatures. 
 
 
 
 
 
 
 
 
Figure 3.8 | hCp blue crystals using the hanging-drop vapour diffusion method at 293 K. Precipitant 
solution of 8% PEG 20K, 6% PEG MME 550, 0.1 M NaAc, 0.4 M Na formate pH 5.7 and 1 mM CuSO4 using 
the hanging drop method at a protein:precipitant proportion of 2:1. 
 
 
 
 
 
 
 
 
Figure 3.9 | hCp blue crystals using the hanging-drop vapour diffusion method at 277 K. Precipitant 
solution of 8% PEG 20K, 6% PEG MME 550, 0.1 M NaAc, 0.4 M Na formate pH 5.7 and 1 mM CuSO4 using 
the hanging drop method at a protein:precipitant proportion of 2:1. 
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Some other modifications were made to this condition. Different concentrations of MPD, glyc-
erol and isopropanol were added to the reservoir using the precipitant solution 8% PEG 20K, 6% 
PEG MME 550, 0.1 M NaAc, 0.4 M Na formate pH 5.7 and 1 mM CuSO4 in an attempt to slow the 
evaporation and get fewer and bigger crystals but no improvements were achieved. Since no more 
improvements could be established to have better hCp crystals, the precipitant solution 8% PEG 
20K, 6% PEG MME 550, 0.1 M NaAc, 0.4 M Na formate pH 5.7 and 1 mM CuSO4 was used and 
crystals grown on this condition were transferred to a cryoprotectant solution and analyzed by X-ray 
diffraction. The use of additives and a cross linking assay were also performed. Another condition 
previously described (Zaitseva et al., 1996) was also investigated and several modifications were 
performed in a search for bigger and better crystals (table 2.7). These condition using the vapour-
diffusion method and as precipitant solution 3% PEG 20K, 0.25 M KCl and 0.1 M NaAc pH 5.5 at 
277 K. When trying to reproduce this condition some alterations where made and blue crystals have 
grown at 293 K using the hanging-drop technique and 10% PEG 20K, 0.4 M NaCl and 0.1 M NaAc 
pH 5.7 at 1:1 proportion. However, this condition was not reproducible. Also 1 mM CuSO4 was add-
ed to the condition at 277 and 293 K in an attempt to stabilize the protein but again no crystals have 
grown. Searching on the PDB (http://www.rcsb.org/pdb/home/home.do) another hCp structure with 
the code 4ENZ was achieved using crystal grown in a precipitant solution of 40% MPD, 0.1 M NaCl, 
0.1 M NaOAc pH 4.6 and 0.01 M CaCl2 at 280 K using the sitting drop vapor diffusion method. This 
condition was reproduced and some alterations were made in an attempt to have better crystals 
(table 2.8). The hanging-drop method was also used and the pH of the solution was changed for 5.6 
since an acidic pH causes some destabilization on copper centers. However, no crystals had grown 
under these conditions.  
Also, hCp into 0.1 M bicine pH 8-5 and 0.15 M NaCl at 40 mg/mL was used in an attempt to 
get crystals. The precipitant solution 8% PEG 20K, 6% PEG MME 550, 0.1 M NaAc, 0.4 M Na 
formate pH 5.7 and 1 mM CuSO4 was used at 293K and some blue hexagonal crystals have grown 
on the drops and were sent for X-ray diffraction analysis. 
 
3.3.1.1. Co-crystallizations: FeCl3, CuSO4, CoCl2 
In an attempt to better stabilize the hCp crystals in order to obtain better diffracting ones, in-
cubations with FeCl3, CuSO4 or CoCl2 were performed and drops in the optimized crystallization 
condition were set. Also it was hoped that if proper diffracting crystals could be obtained some iron, 
copper or cobalt labile binding sites could be identified. Some crystal were obtained (figure 3.10) and 
sent for X-ray diffraction analysis.  
 
 
 
 
 
 
Figure 3.10 | hCp co-crystals using the hanging-drop vapour diffusion method at 293 K. Incubation 
with 5 mM of a) FeCl3, b) CuSO4 and c) CoCl2.  
a)                                          b)                                                     c) 
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3.3.1.2. Additive screen 
The additive screen was performed as described in 2.2.3.3 using the hCp optimized crystalli-
zation condition 8% PEG 20K, 6% PEG MME 550, 0.1 M NaAc, 0.4 M Na formate pH 5.7 and 1 mM 
CuSO4. The 96 additives were tested and the hanging-drop plates were incubated at 293 K. Crystals 
appeared after a couple of days. In table 3.3 are listed the additives that allowed the growth of hCp 
crystals. The best crystals seem to be the ones grown in the presence of FeCl3 and CoCl2 which was 
expected as ceruloplasmin is a multicopper ferroxidase and cobalt can occupy the binding places for 
copper stabilizing the protein. Surprisingly, the presence of CuSO4 inhibited the growth of hCp crys-
tals. This might be due to an excess of copper which causes protein precipitation. Also, the pres-
ence of NADH, TCEP and glycylglycylglycine seems to be very favorable to the growth of hCp crys-
tals. These crystals were tested in house by X-ray diffraction but unfortunately they did not diffract. 
Some were sent for analysis at a synchrotron facility. 
 
Table 3.3 | Additive screen results on optimized crystallization condition at 293K. 
Code Additive Crystals description Crystal Image 
A4 CoCl2 Blue hexagonal, 0.15x0.15nm 
 
A11 FeCl3 Blue/green hexagonal, 0.1x0.1nm 
 
B7 Sodium fluoride Small blue star shape 
 
B8 Sodium Iodide Colorless small neddles Salt crystals 
C11 Glycyl-glycyl-glycine 2 blue hexagonal crystals 
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Table 3.3 | Additive screen results on optimized crystallization condition at 293K (continued). 
Code Additive Crystals description Crystal Image 
D4 CoCl2 hexamine 
Colorless deform crystals 
Colored blue with Izit 
 
D6 Trimethylamine HCL Blue hexagonal, 01.x0.1nm 
 
D9 NADH Several blue hexagonal crystals 
 
D11 TCEP Some blue hexagonal crystals 
 
D12 Cystein One blue hexagonal crystal 
 
F4 NDSB-201 Small blue hexagonal crystals 
 
F11 Octyl D glucoside Several little blue cubic crystals 
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3.3.1.3. Seed Screen 
It is known that if seeds are introduced into a crystallization drop, the level of supersaturation 
required for nucleation and subsequent crystal growth is lower and so seeding has become a well 
established strategy during the optimization of crystallization conditions. It could be macro seeding, 
transferring crystals from its mother drop to a fresh drop in order to allow the growth of the crystal; 
streak seeding, using a horse hair to touch a bad shape crystal and pass it trough new drops with 
crystallization solution or protein concentration modifications in a attempt to get better crystals; or a 
seed screen. The seed screen was performed in an attempt to find a new hCp crystal form. A previ-
ous study (Ireton and Stoddard, 2004) described a method where crystals with low diffraction are 
used to seed into other conditions and a crystal form with 10% reduction in the unit cell were ob-
tained. To perform this screen hCp crystals grown in crystallization solution of 8% PEG 20K, 6% 
PEG MME 550, 0.1 M NaAc, 0.4 M Na formate pH 5.7 and 1 mM CuSO4 at 293 K were used as 
microseeds and introduced into the Structure I+II crystallization screen with hCp at 50 mg/mL in a 
search for a new crystalline form. Unfortunately, almost every drop was precipitated what indicates 
an excesses of protein concentration. The assay should be repeated using hCp at a lower concen-
tration. 
  
3.3.2. Crystallization screenings 
After the dialysis of hCp in 0.1 M NaAc pH 8.8 and 0.1 M NaCl to 0.1M bicine pH 8.5 + 0.15M 
NaCl crystallization screenings were performed for hCp in both buffers. When a hit condition in a 
crystallization screen is observed scaled up drops are made in order to reproduce the crystals and 
then improve their size and shape. Usually the sitting-drop vapour-diffusion method is used as the first 
attempt. Sometime both sitting-drop and hanging-drop techniques are used in a search for the best 
method. The drop proportion is usually the same as in the crystallization screen (1:1) and then some 
modifications are made when trying to get better crystals. 
3.3.2.1. Commercial screens: the hCp challenge 
All the commercial crystallization screens performed are described in table 2.5. In table 3.4 
are described the hit conditions on crystallization screens performed with hCp in 0.1 M NaAc pH 8.8 
and 0.1 M NaCl. The conditions where any crystalline form was observed are described. 
In figure 3.11 there are some images as examples of some crystalline forms found using the 
commercial crystallization screens. There are some irregular shape crystals that have to be im-
proved in shape and size and scaled up drops were performed. 
Some crystallization screens were also performed using hCp at 40 mg/mL in 0.1M bicine pH 
8.5 and 0.15 M NaCl. Screens Stura Footprint HT, Structure I+II and Nextal MPD were performed 
and hit conditions are listed in table 3.5. Best condition was found at Stura footprint screen, D5, 
0.1M NaAc pH 5.5, 12% PEG 5K (figure 3.12). This same condition was a hit when using hCp in 0.1 
M NaAc pH 8.8 and 0.1 M NaCl. The scale up of these conditions was not performed. 
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Table 3.4 | Crystallization screen hit conditions. Using hCp in 0.1 M NaAc pH 8.8 and 0.1 M NaCl. 
Screen HT hCp (mg/mL) Code Condition Description 
Structure I+II 50 A9 20% isopropanol, 20% PEG 4K, 0.1 M Na citrate Microcrystals 
  G2 30% PEH 5K, 0.1M MES, 0.2M AmSO4 Microcrystals 
  H10 10% PEG 1K, 10% PEG 8K Microcrystals 
 25 A6 0.1M NaAc pH 4.6, 8% PEG 4K Crystals 
  B2 0.2M AmSO4, 0.1M Na cacodylate pH 6.5, 30% PEG 8K Microcrystals 
  B3 0.2M MgAc, 0.1M Na cacodylate pH 6.5, 20% PEG 8K Microcrystals 
  B6 0.2M NaAc, 0.1M Na cacodylate pH 6.5, 30% PEG 8K Microcrystals 
  B8 0.2M CdAc, 0.1M Na cacodylate pH 6.5, 18% PEG 8K Microcrystals 
  C5 0.1M NaHepes pH 7.5, 1.4 M Na citrate Microcrystals 
  D7 0.2M AmSO4, 30% PEG 4K Microcrystals 
  D8 2M AmSO4 Microcrystals 
  E8 0.2M AmPO4, 0.1M Tris pH 8.5, 50% MPD Microcrystals 
  E10 0.01M NiCl2, 0.1M Tris pH 8.5, 20% PEG 2K Microcrystals 
  F11 1.6M AmSO4, 0.1M MES pH 6.5, 10% dioxane Microcrystals 
  G3 0.01M ZnSO4, 0.1M MES pH 6.5, 25% PEG550 Microcrystals 
  H2 0.1 M CdCl2, 0.1M NaAc pH 4.6, 30% PEG400 Microcrystals 
  H5 0.01M CTA13, 0.5M NaCl, 0.1M MgCl2 Microcrystals 
Index 50 H1 25% PEG3350, 0.1M tris pH 8.5, 0.2M MgCl2 Crystalline dust 
PEGs suite 50 Microcrystals and precipitate in almost all conditions  
SaltRX 50  No hit condition  
Stura Footprint 50 & 25 C8 0.1M Na Hepes pH 7.5, 45% PEG 600 Microcrystals 
  D2 0.2M imidazole malate, 15% PEG 4K Blue crystals 
  D3 0.2M imidazole malate pH 6, 20% PEG 4K Small blue crystals 
  D5 0.1M NaAc pH 5.5, 12% PEG 5K Blue crystals 
  D9 0.1M AmAc pH 4.5, 9% PEG 10K Deformed crystals 
  G5 12% PEG 8K, 0.2M AmSO4 Microcrystals 
  G6 18% PEG 8K, 0.2M AmSO4 Microcrystals 
  G7 24% PEG 8K, 0.2M AmSO4 Microcrystals 
  H7 20% PEG 4K, 15% isopropanol, 0.1M Na citrate ph 5.5 Crystals 
  H9 9% PEG 8K, 0.005M ZnAc, 0.1M Na Cacodylate pH 6.5 Many microcrystals 
Pact premier 50 C10 20% PEG 6K, 0.1M Hepes pH 7, 0.2M MgCl2 Microcrystals 
  C11 20% PEG 6K, 0.1M Hepes pH 7, 0.2M CaCl2 Microcrystals 
  D10 20% PEG 6K, 0.1M Tris H 8, 0.2M MgCl2 Spherulites 
AmSO4 suite 50 E4 0.8M AmSO4, 0.1 M Hepes pH 7 Spherulites  
  G4 0.1M NaHepes pH 7.5, 1M AmSO4 Colorless crystals 
  H3 5% PEG 400, 2M AmSO4, 0.1M MES pH 6.5 Blue thin plates 
MIDAS 50 A1 50% PPG400, 5% DMSO, 0.1 Na Hepes pH 6 Blue quasi-crystals 
  E4 0.8M AmSo4, 0.1M Hepes pH 7 Spherulites 
  H6 30% poliacrilate5100, 10% ethanol, 0.1M MES pH 6 Thin plates 
Natrix 50                  Almost all conditions have colorless crystals; might be Mg crystals 
Nextal MPD  50 A9 40% MPD, 0.2 M Am iodide Blue small crystals 
  A12 40% MPD, 0.2 M AmCl2 Blue small crystals 
  F11 40% MPD, 0.1M NaAc pH 4.6, 0.2M CaCl2 microcrystals 
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Figure 3.11 | hCp blue crystals grown in some screen conditions. a) Stura footprint, D5: 0.1M NaAc pH 
5.5, 12% PEG 5K; b) Stura footprint, D9: 0.1M AmAc pH 4.5, 9% PEG 10K; c) Nextal MPD, A12: 40% MPD, 
0.2 M AmCl2. 
 
Table 3.5 | Crystallization screen hit conditions. 
Using hCp 40 mg/mL in 0.1 M bicine pH 8.5 and 0.15 M NaCl. 
Screen HT Code Condition Description 
Structute I+II B8 0.2M CaAc, 0.1M Na cacodylate pH 6.5, 18% PEG8K Microcrystals 
 B6 0.2M NaAc, 0.1M Na cacodylate pH 6.5, 30% PEG8K Microcrystals 
Stura Footprint D5 0.1M NaAc pH 5.5, 12% PEG 5K Crystal plates 
MPD  No hits observed   
 
 
 
 
 
 
 
Figure 3.12 | hCp blue crystals grown in a screen condition. Stura Footprint, D5: 0.1M NaAc pH 5.5, 
12% PEG 5K. 
 
3.3.2.2. Scaled up drops 
Some of the most promising hit conditions in the crystallization screens performed with hCp in 
0.1 M NaAc pH 8.8 and 0.1 M NaCl were scaled up. Unfortunately, these assays were not very 
successful. A great part of the scaled up condition did not result in any crystals. An exception was 
observed and some crystals could be grown in a scaled up condition (figure 3.13, a). The A12 
condition from Nextal MPD screen (40% MPD, 0.2 M AmCl2) did successfully originate small blue 
crystals at 277 K in a few days that grew until 0.05x0.05nm. In an attempt to improve the size of 
the crystals AmSO4 was used instead of AmCl2 in the crystallization solution, since this protein 
seemed to be stabilized in the presence of this salt (table 3.4). Bigger blue crystals were obtained 
using this 45% MPD and 0.2 mM AmSO4 with the hanging-drop method also at 277 K (figure 3.13, 
b). Those crystals were freeze and analyzed by X-ray diffraction at synchrotron facilities. 
a)                                                              b)                                                                 c) 
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Figure 3.13 | Scaled up hit conditions and hCp blue crystals. Hanging-drop method at 277K with precipi-
tant condition a) 40% MPD, 0.2M AmCl2; b) 45% MPD, 0.2M AmSO4.  
 
3.3.2.3. Optiscreen 
The Optiscreen is an in house screen created to improve some crystals that cannot be im-
proved using other techniques. The idea behind this screening is to use the evaporation of some 
solutions placed in the reservoir to help the growth of protein crystals in a condition previously opti-
mized in the drop. In this case crescent concentrations of NaCl, PEG3350, AmSO4 and MPD as 
reservoir solutions were used. The optimized crystallization solution 8% PEG 20 K, 6% PEG MME 
550, 0.1 M NaOAc, 0.4 M Na formate pH 5.7 and 1 mM CuSO4 was applied. First, no crystals were 
observed in any of the conditions and so it was added to each reservoir NaOAc and Na formate pH 
5.7 to a final 0.1 and 0.2 M, respectively. These reservoir solutions were not added to the drops. 
This way the equilibrium in the drops moved in a way that allowed the growth of hCp crystals in 
some conditions using MPD at 35%, 40%, 45% and 50% in the reservoir. In the figure 3.14 there are 
showed some of the crystals obtained. They are light blue hexagonal crystals but are much thicker 
than the ones grown in the normal condition (figure 3.8). Several attempts to reproduce this crystals 
were made but with no success. Scaled up drops were also performed but it was not possible to 
grown this crystals in a scaled up condition. These crystals were cryopreserved and sent to X-ray 
diffraction analysis. 
. 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 | hCp blue crys-
tals grown using the 
optiscreen at 293 K. 
a) 40% MPD in the reservoir; 
b) 45% MPD in the reservoir. 
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3.4. Ceruloplasmin and neurotransmitters crystallization 
One of the aims of this study is the determination of the tridimensional structure of cerulo-
plasmin in combination with neurotransmitters in order to identify its binding site and the residues 
involved in this stabilization. The neurotransmitters serotonin, epinephrine, dopamine and L-dopa 
were investigated mainly because of its role on brain homeostasis and functions. Thus, co-
crystallization assays where performed using the previous optimized condition for hCp crystallization 
and also some commercial screens were performed. 
3.4.1. Co-crystallization 
Incubations of ceruloplasmin, in 0.1 M NaAc pH 8.8 and 0.1 M NaCl, with neurotransmitters 
were performed at 4ºC (table 2.9). Commercial screens were performed using different incubations 
with hCp at different concentrations combined with different concentrations of neurotransmitters. It is 
to notice that incubations with neurotransmitters turned from blue to red (epinephrine), brown (do-
pamine, green (serotonin) and grey (L-dopa) after a few hours. Unfortunately, no hit conditions were 
found. Almost all conditions in the different screen used (table 2.10) were precipitated. Also, some 
scaled up drops where set using these incubations and the optimized condition, 8% PEG 20K, 6% 
PEG MME 550, 0.1 M NaAc, 0.4 M Na formate pH 5.7 and 1 mM CuSO4. No crystals could grown 
on the performed drops and only precipitate could be observed. However, when in the presence of a 
lower concentration of neurotransmitter (1mM) the drops seemed more clear and with some tenden-
cy to crystallize. No efforts were made on this and instead soaking experiments were performed. 
 
3.4.2. Soaking experiments 
Several soaking experiments were performed using hCp crystals grown mainly in the opti-
mized condition 8% PEG 20K, 6% PEG MME 550, 0.1 M NaAc, 0.4 M Na formate pH 5.7 and 1 mM 
CuSO4. These crystals of different sizes were transferred for a stabilizing/cryoprotective solution 
(section 3.5.) and then soaking with the neurotransmitters was performed (table 2.11). The resulting 
crystals changed color depending upon the neurotransmitter soaked (figure 3.15). The blue crystals 
turned brownish when soaked with dopamine and orange or red (depending on the concentration) 
with epinephrine. Crystals soaked with L-dopa turned grey and with serotonin light blue/greenish.  
Because of the crystals handling from one solution to another they get sometimes injured. Also, the 
higher concentrations of neurotransmitters cause some cracks on the crystals. These damages will 
interfere and diminish the diffracting power of the crystals that have already poor diffraction. As pre-
viously described these crystals grown in the optimized described condition have a high solvent 
content which makes these crystals very fragile. A method to try to improve or diminish the fragility 
of the crystals is the use of crosslinking by gluteraldehyde. Glutaraldehyde is a linker that binds 
lysines and allows the stability of the protein molecules and its approach to each other. This can 
sometimes improve the diffracting power of a given crystal. However, an excess of glutaraldehyde 
or the time of exposion can cause deformed crystals that will lose diffraction. Thus, this technique 
relies primarily on lysine residues so the number of lysines as well as temperature can be two signif-
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icant variables influencing crosslinking time. Ceruloplasmin as ~6% of lysine residues and crosslink-
ing experiment was performed by 30 min, 1 hour and 2 hours. These crosslinked crystals are more 
resistant to manipulation and hopefully to the effect of the neurotransmitters soaking. Thus, these 
crystals were transferred to new stabilizing drops and soaked with the neurotransmitters. Although 
the crystals should be more resistant some bad shape crystals and even some cracked crystals 
resulted from the soaking experience. Those crystals were sent for analysis. 
Other approach was to use crystals grown in the presence of FeCl3 that seem more robust 
and oak it with the neurotransmitters. Again, some crystals cracked and are full of precipitate due, to 
the FeCl3, that is very difficult to remove without damaging the crystals (figure 3.16). Nevertheless, 
all soaked crystals were freeze and sent for analysis to a synchrotron facility and for data collection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 | hCp crystals soaked with neurotransmitters. Crystals of about 0.15 x 0.15 nm (but thin) 
were incubated with a) 5 mM dopamine for 5 H or b) for 20 H and c) 10 mM incubated for 20 H; crystals in-
cubated with d) 3 mM epinephrine for 20 H, e) 5 mM for 5 H and f) 10 mM incubated for 20 H; crystals incu-
bated with g) 2 mM L-dopa for 20 H and h) 5 mM for 5 H and i) 5 mM serotonin for 20 H. 
a)                                                        b)                                                       c) 
d)                                                        e)                                                        f) 
g)                                                       h)                                                        i) 
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Figure 3.16 | hCp crystals grown in presence of FeCl3 and soaked with neurotransmitters. Soaking 
was performed by 20H with 5 mM a) epinephrine, b) dopamine, c) serotonin and d) L-dopa. 
 
3.5. Crystals cryoprotection 
Prior to freeze crystals for X-ray analysis it is necessary to protect them against the cold tem-
peratures. To do so crystals need to be transferred to an optimum cryoprotectant solution capable of 
preserve the crystals in their form and diffraction. Several cryoprotectants were added to the crystal-
lization condition in order to found the best one in preserving the crystals: 25% PEG MME 550, 25% 
ethyleneglycol, 20% glycose, 25% MPD and drops were set as described in the section 2.2.4.   
When the crystals were transferred into the cryoprotectant solutions but past 30 min the crys-
tals started to dissolve into those drops with 25% glycerol. Those in ethyleneglycol and glucose also 
seemed to start dissolving. Crystals in MPD seemed fine and the ones in 35% PEG MME 550 were 
more stable for a longer time. 
Crystals were sent for X-ray diffraction analysis to confirm which cryoprotectante would be 
better and 35% PEG MME550 was chosen. This PEG is already part of the crystallization condition 
and an increase in its concentration seems to stabilize the grown crystals and has also a 
cryoproctectant power, being used as a cryoprotectant solution on this study.   
 
3.6. Crystals analysis 
All crystals sent for X-ray diffraction analysis were kept at 100 K in liquid nitrogen in the 
cryoprotectant solution (8% PEG 20K, 35% PEG MME 550, 0.1 M NaAc, 0.4 M Na formate pH 5.7). 
Some crystals were tested using the in house X8 Proteum diffractometer AXS system at Macromo-
lecular Crystallography Unit at Instituto de Tecnologia Química e Biológica (UNL), or at the Europe-
an Synchrotron Radiation Facility at Grenoble, France, at beamline ID-14 and ID-23. The crystals 
analyzed at in house diffractomer did not exhibit a diffraction pattern. They were probably to small 
for the in house detector and so their diffraction could not been measured. 
At ESRF several data was collected on crystals but structural analysis was not yet performed. 
Several hCp crystals diffracted at 3.5 Å. hCp crystals soaked with epinephrine diffracted at 3.5 Å and 
3.8 Å. hCp crystals soaked with serotonin diffracted at 4.6 Å. 
a)                                         b)                                             c)                                         d) 
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4. DISCUSSION 
Normal iron and copper metabolism is essential to cell function and healthy body homeostasis 
as these elements are cofactors of several enzymes important for essential biological functions. The 
ability of these metals to participate in one-electron exchange reactions is the key for their essentiali-
ty but at the same time these elements are responsible for the generation of free radicals, trough 
Fenton reaction, that injure cells leading to death. A tight control of cellular copper and iron levels is 
crucial (Arredondo and Nunez, 2005). 
Human ceruloplasmin is the molecular linker between the copper and iron metabolism and its 
importance in the homeostasis of human body has been implied in some neurological diseases. This 
plasma cuproenzyme has ferroxidase activity, oxidizing Fe2+ to Fe3+ and incorporating it into 
apotransferrin (Osaki et al., 1966). Also the role of hCp might be an efficient control of the level of 
ferrous iron oxidation without the production of hydrogen peroxide as an end product (Giurgea et al., 
2005; Gutteridge, 1978). hCp has also aminoxidase activity being important in regulating the level of 
amine stress hormones in the bloodstream and brain.  
In aceruloplasminemia there are low levels of iron in the plasma and its accumulation in the 
tissues, including brain (Harris et al., 1998). The increased levels of iron deposited in the brain, as 
well as the mental deterioration, suggest a connection as found in other neurodegenerative diseases 
(Gonzalez-Cuyar et al., 2008). A possible consequence of iron high levels in the brain is the for-
mation of reactive species and lipid peroxidation which can lead to tissue damage and neuronal cell 
death (Yoshida et al., 2000). Thus, hCp is thought to have an important role in neurodegenerative 
diseases such as Alzheimer’s or Parkinson’s (Floris et al., 2000).  
In Alzheimer’s disease the neurons specifically have reduced levels of ceruloplasmin com-
pared to control cases, possibly allowing the iron to accumulate unchecked, contributing to the neu-
ronal degeneration (Castellani et al., 1999). Alzheimer’s disease is the most common disease asso-
ciated to degenerative dementia and the cause is not well understood. It is prevalent in people over 
65 years of age affecting about 27 million people worldwide (0,4%) (Brookmeyer et al., 2007). There 
is no cure for this disease which is progressive and leads to death. The current treatments help with 
the symptoms but there are not available treatments that stop or reverse the symptoms or the pro-
gression of this disease. The cause for most Alzheimer’s cases is still unknown. Only 1-5% of the 
cases have genetic causes. The deposition of -amyloid plates as been described as the fundamen-
tal cause for these disease (Hardy and Allsop, 1991) but some other hypotheses include the re-
duced synthesis of acetylcholine (Francis et al., 1999), the formation of neurofribrillary tangles of tau 
protein (Goedert et al., 1991), the myelin breakdown with iron release causing neuronal damage, 
oxidative stress (Su et al., 2008) and the loss of norepinephrine (Heneka et al., 2010). As hCp is 
important for oxidative stress control and amine neurotransmitters oxidation the role of this protein in 
this neurodegenerative disease might be of importance but is not yet fully understood.  
 Parkinson’s disease is the second most common neurodegenerative disorder associated to 
motor symptoms resulting from the death of dopamine-generating cells in the substantia nigra 
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caused by the accumulation of -synuclein in neuronal Lewy-bodies. There is no cure for this dis-
ease affecting 7 million people worldwide (Elbaz and Moisan, 2008) and the treatment is mainly 
through the use of L-dopa and dopamine agonists. In PD the neuronal death causes iron release 
increasing the oxidative stress and again hCp can have a neuroprotective role but also cause the 
enhanced oxidation of dopamine.   
To know more about the role of cerulopalsmin on the oxidation of neurotransmitters and its 
role on brain homeostasis it is essential to determinate the tri-dimensional structure of ceruloplasmin 
in complex with de neurotransmitters. This can be very useful to understand better this association 
and which protein residues are implied in the binding and stabilization of these complexes. 
The primary source of structural information for protein-ligand complexes is X-ray crystallog-
raphy. This is the most successful method to determine macromolecular 3D structures but has some 
limitations. The biggest one is to obtain good diffracting protein crystals. The high content of solvent 
(30-70%) makes the crystals very susceptible to damage in handling and by X-rays which can cause 
disordering of molecules within the crystal (Acharya and Lloyd, 2005). The radiation damage can be 
reduced by collecting data at liquid nitrogen temperatures and so crystals are kept at 100 K during 
X-ray analysis. Also some efforts can be performed during crystallization in order to diminish the 
solvent content in crystals or improve the crystal diffraction capability.   
  
4.1. Ceruloplasmin purification, stability and solubility for crystallization 
For protein crystallization a highly pure concentrated amount of the protein is needed is order 
to have good homogeneous crystals. If a protein sample is not >95% pure the chances of getting it 
to crystallize decrease considerably. In this present study the hCp sample was previously obtained 
from human sera using the Broman & Kjellin method (Moshkov et al., 1979) and a final gel filtration 
step was performed to eliminate some aggregates and smaller peptides resulting from protein deg-
radation. Plasma ceruloplasmin has 132 kDa and it was possible to separate it from bigger aggre-
gates but the smaller peptides were still present in the purified protein sample. Protein concentration 
was performed using a membrane filter with a cutoff of 100 kDa in an attempt to separate the de-
graded peptides. Although not all peptides could be removed from the protein sample it was present 
at a lower concentration and sample final achieved at a concentration of 60 mg/mL. Ceruloplasmin 
crystals could be obtained using a previously described crystallization condition (Bento et al., 2007). 
When intending to crystallize a protein, besides being highly pure and concentrated, the sam-
ple needs to be stable at a buffer that confers solubility avoiding aggregation. Differential scanning 
fluorometry was used to evaluate the stability of hCp combined with iron, copper and also cobalt by 
reading the melting temperature of the protein. The presence of iron did not change much the Tm for 
hCp in its purification buffer which is expected as iron is implied in a transition reaction with a high 
Vm for this protein. Copper stabilized globally the hCp exhibiting only a one-transition melting curve. 
It is know from some mutants found in vivo in aceruloplasminemia patients that mutations affecting 
the binding or stabilization of copper in copper centers can lead to unstable protein that undergoes 
degradation. Although cobalt is thought to bind to copper sites its presence seems to destabilize 
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hCp globally and stabilize a specific domain of the protein. As copper seems to stabilize this protein 
the buffer screen using DSF was performed with and without CuSO4. 
As copper gets unstable at acidic pH the protein is unstable at low pH. Ceruloplasmin seems 
to be more sable between pH 8 to 10, although its isoelectric point is 5.5 (figure 3.4). Nevertheless, 
in the presence of CuSO4 the protein seems to be stable at pH between 6 and 8.5 (figure 3.5). At 
more basic pH hCp seems to precipitate maybe due to the excess of copper. Several conditions 
were chosen as being good stabilizing buffer solutions for hCp (figure 3.6) and were tested for solu-
bility ability by DLS and the best one was chosen to keep hCp stable for further crystallization (table 
3.2). The 0.1 M bicine pH 8.5 and 0.15 M NaCl buffer solution showed one intensity peak for a pro-
tein with a molecular weight close to hCp’s molecular weight. This indicates the presence of only 
one protein state in solution confirming hCp solubility in this buffer. 
 
4.2. Ceruloplasmin crystallization 
To have good diffracting crystals is important to have highly pure stable protein. A crystalliza-
tion condition described previously (Bento et al., 2007) was used to perform hanging-drop vapour-
diffusion technique with hCp in 0.1 M NaAc pH 8.8 with 0.1 M NaCl, the purification buffer, and in 0.1 
M bicine pH 8.5 with 0.15 M NaCl. The protein crystallized using both buffers into 0.05x0.05 nm blue 
hexagonal crystals. These crystals were improved by the addition of 1 mM CuSO4 into the crystalli-
zation condition and some condition parameters alteration. Thicker crystals were sent to X-ray anal-
ysis and were further use for soaking with neurotransmitters. 
Crystals were obtained when performing the additive screen using the improved crystallization 
condition. The presence of CoCl2, FeCl3, glycylglycylglycine, NADH and TCEP was favorable to the 
growth of bigger and thicker crystals. As previously described iron and cobalt bind to hCp and alt-
hough DSF results seemed to indicate that those metals do not cause a great impact in protein sta-
bilization, for crystallization the presence of these elements seemed to be favorable. Glycylglycyl-
glycine is the tri peptide of glycine and has been reported has capable of increase protein solubility 
(Ghosh et al., 2004) and that can act as linker facilitating protein crystallization. It has been de-
scribed that the presence of NADH enhances the ceruloplasmin catalyzed oxidation of 
catecholamines (Lovstad, 2006). It seems that the presence of NADH also stabilizes hCp better for 
crystallization. TCEP is a sulfhydryl protective reducing agent. Reducing agents are typically used to 
prevent the oxidation of free sulfhydryl residues in cysteines in the proteins and can help crystalliza-
tion. This oxidation can lead to non-specific aggregation of the sample, sample heterogeneity, inac-
tivity, or denaturation of the sample. However, none of those crystals did diffract when tested in the 
in house diffractometer. This might be due to the fact that crystals are too small for the capacity of 
the beam. Nevertheless, crystals were sent for analysis at synchrotron facilities.   
Also co-crystals of hCp in combination with FeCl3, CuSO4 or CoCl2 have grown in the opti-
mized crystallization condition, in order to stabilize the ceruloplasmin crystals improving its diffraction 
and to identify the binding sites for these elements. Unfortunately, those crystals only diffract at 3.5 -
3.8 Å and no electronic density map could be detected for any of these three metals.  
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To produce crystals with a higher diffraction power from crystals grown at the optimized condi-
tion described, the seed screen was performed. Although if seeds are introduced into a crystalliza-
tion drop, the level of supersaturation required for nucleation and subsequent crystal growth is lower, 
the conditions for this to occur need to be optimized. No crystals could grow in the present seed 
screen and almost all drops were precipitated. This indicates a too high concentrated protein which 
causes it to come out from solution and precipitate. Another seed screen could be repeated using 
lower protein concentration and also other crystallization screens can be used in a search for new 
crystals. Nextal MPD or Stura Footprint could be the first ones to try since several conditions were 
hit conditions when these screens were performed. 
Although several crystallization screens were performed at different temperatures and using 
different protein concentrations not many promising hit conditions were observed. There were sev-
eral conditions where microcrystals and spherulites were observed. It seems that hCp has some 
tendency to crystallize but the crystals are too small or have irregular shape. The only condition 
scaled up and optimized that gave rise to blue crystals was from Nextal MPD screen. It seems that 
ceruloplasmin crystallizes best in the presence of MPD at lower temperatures. It has been already 
described and deposited on the PDB a hCp structure using crystals grown in a precipitant solution of 
40% MPD, 0.1 M NaCl, 0.1 M NaOAc pH 4.6 and 0.01 M CaCl2. These crystals could not be repro-
duced on this study, but blue hexagonal crystals of 0.1x0.1 nm have grown in presence of 45% MPD 
and 0.2M AmSO4 and were sent for analysis. Also, at Optiscreen crystals appeared when using 
MPD as reservoir solution. These crystals were again hexagonal shaped but very thick (figure 3.13) 
which could be good for a good diffraction power, however they were too small and did not diffract.   
 
4.3. Ceruloplasmin and neurotransmitters crystallization 
As one of the objectives of this work is to determine the tri-dimensional structure of cerulo-
plasmin in complex with neurotransmitters efforts were made to have co-crystals of these complex-
es. However, co-crystallization is not always well succeeding. Complexes of protein-ligand are usu-
ally more stable which makes co-crystallization easier but sometimes crystallization conditions can-
not be established. Although different incubations with different concentrations of hCp combined with 
different concentrations of neurotransmitters were performed no co-crystals could be obtained and 
the drops were mainly precipitated. No crystals could be obtained neither in the crystallization 
screens or scaled up drops using the optimized conditions for hCp crystals. However, when using 
these conditions with lower concentrations of neurotransmitter the drops seemed to become more 
clear which might indicate that maybe co-crystals are possible to obtain if the concentration of neu-
rotransmitter could be lowered. The problem can be that at lower concentrations of neurotransmitter 
might be then difficult to see it in the crystallographic data, more precisely, in the density map. Thus, 
soaking experiments were performed on hCp crystals. 
hCp crystals were used for soaking with the neurotransmitters. Also crystals in combination 
with FeCl3 were further used for soaking with neurotransmitters. Crystals soaked with neurotransmit-
ters changes color after some hours, which proves that neurotramitters react with ceruloplasmin and 
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are much probably bound. However, these crystals are very fragile and difficult to handle. Some 
crystals cracked after being exposed to neurotransmitters soaking.  Thus, some crystals were 
crosslinked before being soaked with neurotransmitters in an attempt to make them more resistant 
to manipulation and soaking. The times of explosion to gluteraldehyde were between 30 min and 2 
hours. As hCp crystals are already poor diffracting crystals the time of crosslinking has to be short, 
once it can worsen its diffraction. On the other hand too less crosslinking time, and once these crys-
tals have a high solvent content, may not be enough to protect crystals from handling damage. hCp 
crystals grown in presence of FeCl3 were also crosslinked before soaking.  
 
4.4. Crystallography data analysis 
Protein crystals suffer at room temperature from serious X-ray radiation damage. Cryo-cooling 
the crystals to 100 K is a way to dramatically reduce the radiation damage. The cooling process 
needs to avoid the formation of ice crystals in the protein crystal since these destroy the order of the 
protein molecules in the protein crystal (Hope, 1988). It is extremely import to found a good 
cryoprotectant condition. In the case of crystals grown at 45% MDP and 0.2 M AmSO4 no 
cryoprotectant was added once MPD has cryoprotectant properties. For hCp crystal the best 
cryoprotectant found using the optimized condition was 35% PEGMME 550 combined with the opti-
mized crystallization condition, as no diffraction was obtained when analyzing crystals kept on other 
cryoprotectants. 
Crystals analyzed in house did not diffract but that might be due to the small size of the crys-
tals. Some of the crystals sent to ESRF diffracted between 3 Å and 4 Å. Data from hCp crystals and 
hCp combined with neurotransmitters was collected and analyzed for structure analysis. As the 
structure of ceruloplasmin crystallized at identical crystallization conditions was already solved, it will 
be easier to work on the collected data from ESRF. However, due to the crystals low resolution but 
no electronic density could be determined for any neurotransmitter analyzed.  
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5. CONCLUSIONS & FUTURE PERSPECTIVES 
In this study several attempts were made to obtain human ceruloplasmin good diffracting crys-
tals. Although ceruloplasmin is a protein not very difficult to crystallize, because of its higher solvent 
content the diffraction improvement is not very easy to achieve. One of the aims of this study was 
the establishment of a crystal form with reduction in the unit cell in order to obtain a better diffraction 
pattern and thus, a higher resolution structure. It was also very important to have good diffracting 
and resistant ceruloplasmin crystals for further soaking with the neurotransmitters, as the co-crystals 
could not be established.   
To obtain good diffracting crystals stable and soluble protein samples are required. By DSF 
analysis it was determined that copper sulfate is capable of stabilize hCp, since this is a 
cuproenzyme. Not so god results were obtained for iron although hp is a ferroxidase. However, 
when incubating the hCp protein with FeCl3 or even CoCl2 the resulting crystals have a good looking 
aspect. Unfortunately, no diffraction data was collected from these crystals. Also by DSF, and in 
combination with DLS analysis, a new buffer was selected for hCp stabilization and further crystalli-
zation (01 M bicine pH 8.5 with 0.15 M NaCl). However, it was observed that hCp have better crys-
tallization results when using the previously described purification solution buffer (0.1 M NaAc pH 8.8 
and 0.1 M NaCl). Some improvements were made as using additives, performing some seeding and 
crosslinking. That was not here described but also dehydration technique was performed at PETRA 
facilities at Hamburg, Germany. However, when the hCp crystals are subjected to the dehydration 
technique all the structure collapses and the crystals are destroyed. Another form of dehydration is 
the successive transference of grown crystals from drops with optimized crystallization condition for 
new drops with crescent higher concentration of precipitant. This was also tried but the hCp crystals 
are so fragile that the repeated handling damages the crystals and diffraction is lost. 
The combination of ceruloplasmin with copper, iron or cobalt in an attempt to achieve better 
diffracting crystals was not well succeeded as only 3.5A diffracting crystals could be obtained and 
not electronic density for any metal could be determined.  
Another crystallization condition was obtained using the 96 conditions commercial crystalliza-
tion screen Nextal MPD suite from Qiagen. Crystals have grown on hanging-drop vapour-diffusion 
drops with 45% MPD and 0.2 M AmSO4 at 277 K. These small blue crystals were sent to analysis at 
ESFR and there is some untreated collected data.  
Although these crystals grew in a different crystallization solution, so far it is thought that no 
new crystal form could be determined, but some improvements were made on the previously de-
scribed crystallization condition (Bento et al., 2007).  
Thus, some soaking experiments with neurotransmitters could take place. The best diffracting 
crystals were soaked with epinephrine and serotonin and we look forward to work on the data sets 
analysis from ESRF and solve the structural data. It is expected that at least one data set could be 
solved and at least one combined structure of ceruloplasmin with a neurotransmitter could be de-
termined.  
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Even if no structure could be solved from this present study some major conclusions can be 
drawn that can help in achieving an improved ceruloplasmin structure in combination with neuro-
transmitters: 
a) the crystallization condition described (Bento et al., 2007) was optimized and better looking 
crystals could be obtained. Some work can be further improved on the cryoprotectant solution; 
b) ceruloplasmin seems rather crystallize in MPD. Some more efforts should be made in this di-
rection. Also the Optiscreen with MPD should be repeated and investigated; 
c) although no crystallization conditions could be established for co-crystallization of hCp with 
any of the neurotransmitters, it seems that it might co-crystallized in the described crystalliza-
tion condition (Bento et al., 2007). Lower neurotransmitter concentration, lower protein con-
centration, lower precipitant concentration or lower temperature are all variants that should be 
investigated; 
d) crystals soaking with neurotransmitters is a way of overcome the problem of having no co-
crystals, but is a more aggressive treatment to the crystals. Also maybe a different stabiliza-
tion condition different from cryoprotectant condition could be determined and introduced. 
The determination of the structures of these hCp-neurotransmitter complexes can be of ex-
treme importance to identify the residues involved in the binding and complex stabilization.  This 
might be crucial to better understand the role of human ceruloplasmin in hormones and brain home-
ostasis and its importance in several neuronal diseases. 
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